cardiac neoplasm rare occurr clinic practic variou frequenc primari secondari malign tumor vari report report approxim most autopsi seri cancer patient's autopsi cardiac malign account cardiac surgeri 0.1 cardiac echograph studi presenc metastat tumor heart usual indic widespread metastas lung carcinoma most commonli encount tumor follow breast pancrea cancer melanoma apart primari pericardi mesothelioma primari cardiac tumor high-grade sarcoma high metastat potenc becom evid earli surgeri symptom non specif occur late diseas affect few patient especi secondari neoplasm heart take cours fast becom symptomat sign cardiac neoplasm divid system symptom fever arthralgia myalgia cardiac symptom congest heart failur arrhythmia chest pain uncommon embol diagnosi actual made easier cardiac echographi cardiac rmi help estim vessel pericardium involv due poor prognosi treatment cardiac metastas restrict best support care primari cardiac neoplasm surgeri carefulli discuss becaus oper intervent follow rapid widespread metastas adjuv chemotherapi avoid most case
object systemat review control trial investig effect exercis intervent cancer patient method studi locat through search seven electron databas medlin embas cochran librari cancerlit psycinfo cinahl sportdiscu scan refer list relev articl contact expert check content list journal avail through zetoc electron tabl content includ trial prospect control involv particip diagnos cancer test exercis intervent type outcom restrict two review independ appli select criteria result thirti-three control trial includ random trial includ review evid physic function increas among exercis furthermor symptom fatigu appear increas few advers effect report insuffici evid determin effect outcom qualiti life result hamper heterogen studi well poor methodolog qualiti data lack long term effect exercis relat cancer recurr surviv conclus preliminari evid exercis intervent cancer patient lead moder increas physic function associ increas symptom fatigu howev imposs current evid determin whether exercis long term benefici effect surviv qualiti life
human tissu factor initi blood coagul besid function involv tumor angiogenesi metastasi studi evalu effici antisens oligonucleotid as-odn select comput predict mrna structur fourteen differ as-odn test three cell line differ origin high content cell line mcf-7 express gene inhibit as-odn as-7 comparison refer investig depend inhibit effici as-odn posit insid potenti target motiv design as-odn shift 2-3 among as-7 on as-odn found effect as-7 cell line t508 obtain moder effect inhibit gene express as-4 j82 cell protein inhibit two as-odn conclus compar inhibit gene express differ cancer cell line found effect as-odn locat translat region mrna suitabl target region as-odn rel independ cell line contrast optim transfect condit depend cell line
coupl decad tremend increas interest biolog properti natur product mean identifi novel small compound potenti clinic medicin flavonoid- flavonoid-like compound percol top due presenc diet constitu report benefici effect divers biolog process diseas condit plant polyphenol antibiot resveratrol found grape nut wine focu studi aim understand full rang health benefici effect interest compound stem earlier observ describ therapeut benefit root orient medicin plant resveratrol first isol constitu grape wine initi work focus link resveratrol benefici cardiovascular effect moder wine intak howev report cancer chemoprevent activ murin model carcinogenesi heighten interest understand anti-cancer activ resveratrol result substanti amount data strongli suggest resveratrol affect process carcinogenesi through varieti differ mechan differ tumor cell type howev coupl recent report provid evid contrari critic review attempt summar find discuss clinic potenti compound deriv light recent conflict report
present studi aim assess differ nordic countri late mortal among five-year survivor childhood cancer case diagnos befor ag year 1960 1989 collect nordic cancer registri total 689 patient identifi five-year survivor extend follow-up 12.3 di mortal analys decad diagnosi site leukaemia hodgkin's lymphoma central nervou system tumour separ analys done cox proport hazard regress framework adjust made gender ag diagnosi hazard ratio calcul relat weight nordic mean base proport five-year survivor countri overal late mortal significantli higher denmark finland norwai sweden explain invers differ five-year surviv differ diminish time disappear period pattern similar both gender disappear differ most probabl effect closer collabor nordic paediatr oncologist develop implement common protocol treatment childhood cancer countri
author develop phantom design cagn phantom compat mri hyperthermia us fundament studi non-invas thermometri ingredi phantom carrageenan gdcl3 modifi agaros modifi nacl conduct modifi nan3 antisept distil water anoth phantom develop cag phantom relax time adjust human tissu us phantom electromagnet heat nacl ad chang conduct phantom clarifi relationship conduct nacl concentr studi examin relationship relax time nacl concentr cagn phantom result show both valu affect nacl experiment result led empir formula express relationship relax rate 1/t1 1/t2 concentr gdcl3 agaros nacl appropri concentr modifi calcul empir formula make specifi phantom requir relax time nacl concentr
paraganglioma rare neuroendocrin neoplasm observ patient ag character children author describ retroperiton paraganglioma diagnos chanc 11-year-old boi aspect retroperiton paraganglioma still under investig treatment choic radic resect surgeri possibl chemotherapeut debulk cyclophosphamid vincristin dacarbazin 131i-mibg radiotherapi prove increasingli us reduc pain associ dissemin diseas facilit surgic resect case appear inoper convent radiotherapi pure palli us reduc pain bone metastas
quinoid quinoid radic phenoxyl radic form estrogen estron diethylstilbestrol de antiestrogen tamoxifen toremifen respons advers effect carcinogenesi radic-scaveng activ estrogen antiestrogen determin quantit induct period method polymer methyl methacryl initi thermal decomposit 2'-azobisisobutyronitril aibn benzoyl peroxid bpo under anaerob condit inhibit rate constant inh x10 estron de tamoxifen toremifen 6-di-t-butyl-4-methyphenol bht 1-3 2-4 6-12 6-13 1-2 respect inh antiestrogen two-fold greater estrogen bht contrast stoichiometr factor number free radic trap on mole antioxid moieti estron de tamoxifen toremifen bht 1.2-1.5 1.8-2.4 0.5-0.9 0.4- 0.5 1.5-1.9 respect fulli oxid valu estron de bht wherea antiestrogen howev valu estron antiestrogen markedli respect suggest complex oxid process result format quinoid quinoid radic phenoxyl radic induct period
aim studi evalu potenti applic 18-fluorodeoxyglucos positron emiss tomographi fdg pet pet/ct cancer screen asymptomat individu subject consist 3631 physic check-up examine 1947 men 1684 women mean ag +/- 52.1 +/- 8.2 non-specif medic histori whole-bodi fdg pet pet/ct ultrasound tumor marker perform patient focal hypermetabol area intens equal exceed level fdg uptak brain consid abnorm interpret neoplasia follow-up period longer on year among 3631 fdg pet includ 1687 pet/ct ultrasound tumor marker examin malign tumor discov examine 1.29 pet find true-posit cancer 80.9 addit cancer screen pet/ct scan pet detect cancer lesion examine howev detect cancer lesion examine sensit fdg pet detect wide varieti cancer high most cancer detect fdg pet resect stage pet/ct local characterist lesion show increas specif pet scan us ultrasound tumor marker complement pet scan cancer screen hepat urolog neoplasm
gynaecolog oncolog dai surgeri deal primarili diagnosi endometri cervic vulvar vagin tumor consciou sedat import techniqu us gynaecolog oncolog dai surgeri associ region anaesthesia goal consciou sedat provid effect pain control complet safeti reduct recoveri time infect risk cost consequ immunosuppress effect opiat surgic stress lead increas suscept post-oper infect possibl lack immunolog defenc cancer patient investig possibl elimin administr opiat minor oper gynaecolog oncolog dai surgeri studi 400 patient ag year underw surgeri us sedat dai hospit annex gynaecolog obstetr depart 2nd univers napl itali patient random two equal studi group accord comput-gener randomis list patient consult anaesthetist three dai befor surgeri case surgeri monitor main vital paramet ecg drug commonli us opioid hypnot benzodiazepin associ local anaesthet us drug pain anxieti reduc sedat amnesia accomplish experi consciou sedat seem best choic gynaecolog oncolog dai surgeri becaus present low toxic short act readili revers low cost final becaus comfort patient moreov possibl elimin administr opiat consciou sedat invas surgic procedur
goal complementari/ altern medicin cam wide us patient rare discuss oncologist understand reason commun gap studi compar physician patient perceiv reason cam us nondisclosur us reaction physician disclosur expect cam patient method cross-section studi assess physician respons 68.3 244 374 outpati respons 65.2 identifi cam user anderson cancer center data summar frequenc compar us chi-squar test main result physician like p&lt 0.001 patient attribut cam us hope chi2 17.7 control chi2 17.5 incur diseas chi2 42.8 nontox approach chi2 50.9 both physician patient agre cam reliev symptom/side effect physician like p&lt 0.001 patient expect cam improv immun chi2 72.2 qualiti life chi2 17.1 cure diseas chi2 42.5 prolong life chi2 58.4 physician patient respond differ p&lt 0.005 reason nondisclosur physician believ patient felt cam discuss unimport chi2 7.9 physician understand chi2 48.1 discontinu treatment chi2 26.4 discourag disapprov us chi2 131.7 patient attribut nondisclosur uncertainti benefit chi2 10.4 ask cam chi2 9.9 physician physician like chi2 9.5 p&lt 0.002 warn risk like chi2 23.5 p&lt 0.001 encourag us patient perceiv conclus oncologist cancer patient hold discrep view cam contribut commun gap nevertheless physician ask patient cam us discuss possibl benefit advis potenti risk
background develop synthet taxan target increas solubl drug improv clinic efficaci reduc side-effect evalu sensit head neck squamou cell carcinoma cell line bm-184476 bm-188797 vitro materi method effect paclitaxel synthet taxan test six recent establish cell line oral caviti scc laryng scc us 96-well plate clonogen assai ic50 valu correspond mean inactiv dose obtain dose respons curv result test cell line consider sensit both synthet taxan compar paclitaxel rule ic50 concentr paclitaxel 4-5.5 time higher bm-184476 bm-188797 sensit drug vari cell line cell line time laps video microscopi show mitot arrest subsequ apoptosi four hour bm-188797 conclus result indic synthet taxan us clinic warrant vitro test combin modal model like concurr chemoradi
19th centuri possibl tumor reject mere bodi's immun defens vision 100 year preclin clinic research field vision cancer immunotherapi becam real multipl tool successfulli enter clinic standard practic non-specif mediat immun defens bcg treatment superfici bladder cancer interferon-alpha treatment chronic myelogen leukemia hairi cell leukemia induc durabl remiss particular antigen-specif mediat immun defens repres promis agent target cancer therapi antibodi-base treatment b-cell lymphoma breast cancer dramat improv diseas respons major toxic larg number antibodi target differ epitop varieti malign cell approach clinic approv allogen stem cell transplant treatment leukemia certain cancer repres first cell-base adopt immunotherapi larg-scale clinic applic experiment cell-base immunotherapi promis clinic perspect includ tumor vaccin adopt transfer autolog tumor-specif effector cell genet transfer tumor-specif cell receptor patient's lymphocyt fact demonstr immunotherapi establish fourth column cancer therapi besid surgeri radiotherapi chemotherapi basi alreadi proven efficaci usual favor toxic profil develop perspect experiment approach rapid expans expect
major head neck cancer occur fifth sixth decad onset patient older year rare event peculiar characterist almost case seri lower preval radic treatment among elderli compar younger patient particular surgeri combin treatment surgeri plu radiat therapi chemotherapi radiat therapi radiotherapi feasibl treatment elderli patient advanc ag group era organ preserv chemotherapi combin paramount import therapeut plan base tumor characterist physiolog rather chronolog ag patient main clinic problem select patient administ anticanc treatment patient ag older complet geriatr assess multidisciplinari approach crucial point
ed-b fibronectin ed-b glycoprotein involv cell adhes migrat express fetal neoplast tissu absent normal counterpart aim studi evalu express glycoprotein relat histolog clinic data determin whether prognost valu patient head neck squamou cell carcinoma hnscc nineti-five case assess ed-b express us immunohistochemistri posit ed-b express significantli associ tumor grade 0.06 primari tumor site 0.02 larynx tumor site associ least ed-b express univari analysi associ diseas-free surviv 0.48 mean time progress clearli shorter tumor posit ed-b express neg express month patient have tumor express ed-b trend signific lower overal surviv multivari analysi 0.06 studi show ed-b express prognost valu patient hnscc
recent year sever countri deceler level pleural mesothelioma rate observ impact asbesto us analys compar countri rel modest incid rate mesothelioma sweden earli respons asbesto us countri on highest incid rate mesothelioma western europ netherland sweden cancer regist provid inform annual incid pleural mesothelioma wherea netherland mortal data provid statist netherland period 1969-2001 netherland among men incid rate consist higher 1.5-2 time sweden wherea among women similar rate observ assum none femal case caus occup exposur asbesto minimum estim etiolog fraction occup exposur asbesto men sweden netherland possibl explan consist higher incid rate netherland sweden includ differ exposur level proport expos subject workforc type asbesto fibr us measur decreas exposur asbesto seem decreas risk pleural mesothelioma both countri among ag group year effect will result level increas pleural mesothelioma both countri decad
purpos half centuri research explor myeloabl high-dose chemo/radiotherapi follow allogen hematopoiet stem cell transplant hct therapi malign nonmalign hematolog diseas continu advanc field chang approach on initi thought fraught insurmount complic on consid standard therapi diseas method order extend allogen hct includ elderli patient repres main popul affect hematolog malign medic unfit undergo convent hct novel non-myeloabl approach develop approach reli graft-vs-tumor effect tumor erad rather high-dose chemoradiotherapi lower toxic convent regimen result result non-myeloabl regimen gratifi chang futur allogen hct advanc possibl basic research studi pre-clinic anim model conclus work focus improv graft-vs-tumor effect achiev better control graft-vs-host diseas
background hermanski-pudlak syndrom hp common genet disord puerto rico children hp bleed most disturb incapacit problem desmopressin 1-deamino-8-d-arginin vasopressin ddavp recommend manag bleed disord character platelet dysfunct hp method nineteen pediatr puerto rican patient hp prolong bleed time test respons administr ddavp result baselin abnorm patient ddavp administr improv two case on 7.2 5.6 min min tabl iii measur remain prolong min patient patient hp gene mutat statist signific correl poor respons ddavp 0.03 conclus ddavp seldom improv puerto rican children hp respons ddavp determin individu platelet transfus remain treatment choic major bleed episod surgic procedur
patient surviv head neck squamou cell cancer hnscc chang significantli year despit progress surgic radiotherapi chemotherapi techniqu immunotherapi rapidli progress altern cancer treatment aim prompt assist bodi's immun system combat diseas number strategi exist includ us dendrit cell natur antigen present cell capabl stimul anti-tumor immun respons encourag work perform us cell vaccin number tumor especi melanoma work head neck cancer encourag advanc dendrit cell presenc head neck squamou cell cancer associ improv prognosi howev due immunosuppress exact mechan remain poorli understood cell function effici prevent stimul effect anti-tumor immun respons patient allow tumor growth continu review summaris current level understand dendrit cell relationship hnscc briefli summaris work dendrit cell cancer relev hnscc dendrit cell head neck cancer possibl caus dendrit cell impair techniqu us restor function method us prime dendrit cell prior us vaccin stimul anti-tumor respons
resveratrol natur occur stylben present grape propos respons posit effect red wine consumpt cardiovascular diseas french paradox recent year molecul propos cancer chemoprevent agent aim present studi investig mechan resveratrol inhibit tumor growth purpos u937 cell expos resveratrol concentr usual present red wine effect prolifer death cell cycl machineri assess u937 cell growth impair due reduc cell prolifer signific induct apoptosi anti-prolif effect associ modul pattern dna distribut reduct g0/g1 particularli g2-m peak accumul phase cell cycl result confirm observ rate [3h]-thymidin incorpor dna significantli reduc resveratrol-treat u937 cell consist observ same experiment condit activ ribonucleotid reductas enzym critic involv process dna duplic decreas alter progress cell cycl depend modul activ cyclin depend kinas inhibitor exposur u937 cultur resveratrol express cyclin well cdk2 increas p21cip significantli reduc data shown report suggest prevent cancer develop exert resveratrol result modul molecul involv regul cell cycl progress block cell phase checkpoint
purpos present studi aim evalu mdr revers activ bromotetrandrin brtet bromiz deriv tetrandrin tet vitro vivo method drug sensit determin us mtt assai vivo effect tet investig us nude mice graft sensit resist human epidermoid cancer cell doxorubicin dox accumul analyz fluorospectrophotometri protein mrna level p-glycoprotein p-gp determin immunocytochemistri rt-pcr respect result brtet 0.25 0.5 micro revers dox resist mdr human breast cancer mcf-7/dox cell dose-depend potenc greater tet same concentr brtet revers vincristin vcr dox paclitaxel resist mdr human oral epidermoid carcinoma kbv200 cell well innat vcr dox resist human hepatocellular carcinoma bel 7402 cell howev brtet show effect valu abov-mention anticanc drug sensit mcf-7 cell revers effect brtet cytotox 5-fluorouracil cisplatin non-p-gp substrat observ nude mice bear kbv200 xenograft left flank xenograft right flank i.p inject mg/kg mg/kg brtet significantli enhanc antitumor activ dox kbv200 xenograft inhibitori rate 33.0 39.2 dox alon inhibit growth kbv200 xenograft 11.6 enhanc brtet xenograft moreov brtet mg/kg revers paclitaxel resist kbv200 xenograft fluorospectrophotometr assai show brtet significantli increas intracellular accumul dox mcf-7/dox cell dose-depend manner brtet inhibit overexpress p-gp mcf-7/dox cell effect mdr1 express conclus brtet show signific mdr revers activ vitro vivo activ relat inhibit p-gp overexpress increas intracellular accumul anticanc drug brtet promis mdr modul eventu assess clinic
background isophosphoramid mustard ipm cytotox alkyl metabolit ifosfamid ifo ipm readi phase clinic trial present preclin studi ipm evalu usag multidos intraven infus protocol method mice dog receiv ipm daili dai singl-dai dose-oral iv-to mice rat monkei review comparison complet toxicolog studi complet mice dog mice dog monkei pharmacokinet studi conduct compar result mice 3-dai schedul ipm calcul 119 mg/kg confid limit 87-134 mg/kg combin sex adult male dog maximum toler dose mtd mg/kg pharmacokinet studi mice dog monkei compar project human dose dog receiv mg/kg ipm 1/2beta 0.99 clearanc constant 1.01 l/h/kg ipm detect 1.5 mg/kg dose mg/kg dose none detect mtd dog mg/kg per dai dai renal tubular necrosi bone marrow failur caus death transient liver renal bone marrow toxic gastrointestin dysfunct low dose &lt mg/kg dog mice receiv 100 mg/kg plasma concentr disappear 1/2alpha min clearanc 8.44 l/h/kg monkei mean 1/2 4.2 median clearanc 1.65 l/h/kg ipm detect dose potenti ipm metabolit detect studi vitro plasma protein bound ipm min incub conclus predict human pharmacokinet paramet dose made allometr analysi us three speci data predict accept start dose mg/m clearanc 39.5 l/h 1/2 min 70-kg patient
tumor express cd95l cd178 fasl apo-1l kill tumor-infiltr lymphocyt phenomenon call tumor counterattack howev present clear whether tumor counterattack relev immun escap mechan character effect cd95l express tumor cell tumor-specif cell establish vitro system tcr cell model tumor antigen preactiv antitumor cell abl kill cd95l cd95l tumor cell cd95l tumor cell kill activ cell vitro inhibit expans cytotox antitumor cell mix lymphocyt tumor reaction vivo cd95l express led delai tumor growth complet tumor reject neutrophil respons delai growth cd95l tumor test mice neutrophil defici import cytotox mechan p47phox -/- ino -/- mice cd95l tumor grew similarli wild-type mice incid growth rate cd95l tumor mice inject neutrophil-deplet isotyp control antibodi same cd95-defici lpr mice tumor growth alter compar wild-type mice taken togeth cd95l mediat tumor counterattack vitro led neutrophil-independ tumor reject vivo
modern cancer therapi strive elimin malign tissu preserv healthi tissu patient's qualiti life antigen-specif immunotherapi approach promis aspect design act tissu express specifi tumour antigen order develop success vaccin adopt transfer protocol longitudin monitor cancer patient take part clinic trial mandatori here vivo expans antigen-specif cell well vivo function statu repres import paramet analys obtain result most close reflect cell' vivo statu function assai carri littl vitro cultur possibl present minireview discuss recent advanc domain
conduct popul-base prospect cohort studi japan examin relationship bodi mass index bmi risk incid cancer cancer individu site bodi mass index calcul self-administ bodi weight height baselin rel risk confid interv calcul multivari proport-hazard model among 539 person 054 women 485 men ag year older free cancer enrol 1984 672 668 women 004 men develop cancer year follow-up women adjust potenti confound cancer associ differ bmi rel bmi 18.5-24.9 1.04 0.85-1.27 bmi 25.0-27.4 1.29 1.00-1.68 bmi 27.5-29.9 1.47 1.06-2.05 bmi 30.0 trend 0.007 higher bmi significantli associ higher risk cancer colorectum breast postmenopaus endometrium gallbladd women men observ significantli increas all-cancer risk among never-smoker overweight obes account 4.5 subject 6.2 never-smoker risk cancer women -0.2 subject 3.7 never-smoker men valu women rang among women report western popul 3.2 -8.8 data demonstr excess weight major cancer risk among japanes women
drug inhibit function heat shock protein hsp90 interest treatment pediatr cancer becaus agent deplet cellular level signal molecul import growth surviv childhood tumor gener preclin data anticip clinic trial hsp90 inhibitor children evalu effect hsp90 inhibitor geldanamycin alon combin ci-platinum -diamin dichlorid cisplatin pediatr tumor cell immunoblot demonstr deplet hsp90 client protein akt type insulin-like growth factor receptor igf1r panel pediatr tumor cell line exposur drug exposur led dramat decreas cell surviv/prolifer mycn-amplifi non-amplifi neuroblastoma cell moder inhibit surviv/prolifer observ rb-defici wild-type osteosarcoma cell treatment neuroblastoma osteosarcoma cell line combin cisplatin result greater addit inhibit surviv/prolifer base median dose analysi exposur drug combin result mark increas nuclear fragment assess termin deoxynucleotid transferas-mediat utp nick label tunel analysi combin exposur abrog abil induc cytoprotect heat shock respons result hsp90 adduct format find suggest hsp90 inhibitor prove us alon compon multi-drug regimen treatment neuroblastoma osteosarcoma
aim develop popul pharmacokinet model simultan analysi oral/intraven cisplatin data order estim mean popul pharmacokinet paramet mainli bioavail cisplatin evalu influenc covari pharmacokinet variabl method pharmacokinet demograph data collect adult patient male/12 femal ag rang 47-76 year receiv 30-min infus oral formul cisplatin 10-30 mg/m2 variou malign both total plasma ultrafilter unbound platinum concentr determin result unbound total platinum concentr ascrib two-compart model first-order absorpt elimin oral bioavail popul estim respect 0.39 0.30 associ intersubject variabl isv peak concentr oral dose occur 1.0 1.6 unbound total platinum respect clearanc central distribut volum unbound platinum significantli relat bodi surfac area bsa mean estim respect l/h associ isv final pharmacokinet model valid us 1000 bootstrap sampl origin dataset conclus both unbound total platinum data allow fair evalu oral cisplatin disposit close estim both absorpt rate oral bioavail result support convent dose adjust cisplatin base bsa
object docetaxel given oral monotherapi result low bioavail &lt previou studi indic intestin efflux pump p-glycoprotein p-gp prevent uptak gut result low system exposur docetaxel purpos studi determin degre enhanc oral uptak docetaxel combin oral administ oc144-093 potent p-gp inhibitor furthermor safeti combin treatment determin whether known function genet polymorph mdr1 gene associ variabl docetaxel pharmacokinet investig patient method proof concept studi carri patient advanc solid tumor patient random receiv on cours 100 oral docetaxel combin 500 oc144-093 follow week later second i.v cours docetaxel flat dose 100 oc144-093 vice versa follow standard i.v docetaxel treatment indic result appar rel oral bioavail docetaxel 26+/-8 oral administ docetaxel combin oral oc144-093 result cmax 415+/-255 auc0-infin 844+/-753 kel 0.810+/-0.296 valu differ significantli i.v administr docetaxel cmax 2124+/-1054 auc0-infin 2571+/-1598 kel 1.318+/-0.785 0.003 0.006 0.016 studi medic well toler most advers event possibl probabl relat oc144-093 docetaxel ctc grade on patient homozyg 3435t/t mutat associ low intestin p-gp express two patient homozyg mutat exon conclus rel appar bioavail most like caus signific effect oc144-093 oral uptak docetaxel larg intrapati interpati pharmacokinet variat found oral well i.v administr docetaxel higher plasma level observ 100 i.v docetaxel 100 oral docetaxel plu 500 oral oc144-093 safeti oral combin good patient evalu determin effect p-gp singl nucleotid polymorph oral pharmacokinet valu docetaxel
background resist chemotherapi partli explain activ membran bound p-glycoprotein competit inhibit p-glycoprotein multidrug resist mdr convert overcom mdr previous studi mdr convert seriou intrins side effect consider influenc pharmacokinet cytotox agent concentr theoret requir convert mdr gf120918 third-gener mdr convert high affin p-glycoprotein given oral perform phase studi escal dose gf120918 combin doxorubicin patient method studi group compris patient advanc solid tumor doxorubicin administ dai cycl gf120918 dai 22-24 cycl dai 29-33 doxorubicin administ dai cycl pharmacokinet both gf120918 doxorubicin studi start daili dose gf120918 increas subsequ cohort steadi state plasma level 100 ng/ml reach start dose doxorubicin mg/m2 increas reach target dose level gf120918 result patient full pharmacokinet data three schedul cycl obtain pharmacokinet gf120918 show linear increas cmax increas dose consider interpati variat target steadi-state plasma level gf120918 exceed patient receiv 400 gf120918 alon twice daili patient receiv 400 gf120918 twice daili combin doxorubicin gf120918 pharmacokinet influenc coadministr doxorubicin doxorubicin auc margin influenc gf120918 highest dose level patient signific increas auc doxorubicinol cycl compar cycl hematolog toxic mainli consist neutropenia sever cycl cycl patient grade neutropenia 0.003 neutropen fever dose-limit toxic doxorubicin dose mg/m2 400 gf120918 twice daili toxic gf120918 limit somnol eight patient occasion gastrointestin complaint conclus gf120918 mdr convert minim side effect dose level yield concentr abl convert action p-glycoprotein vitro doxorubicin dose mg/m2 dai combin 400 gf120918 twice daili dai 1-5 accept regimen clinic trial
previou studi shown epstein-barr viru ebv -encod latent membran protein lmp1 enhanc etoposid-induc apoptosi epitheli cell studi undertaken dissect modul tumor cell apoptosi viral protein us induc system lmp1 express hela cell show herein etoposid-trigger apoptosi evidenc nuclear condens caspas-3 activ enhanc lmp1 lmp1 potenti etoposid-induc process activ caspas-2 model enhanc dissip mitochondri transmembran potenti releas cytochrom respons etoposid moreov cisplatin-trigger activ caspas potenti express lmp1 similar lmp1-mediat enhanc cisplatin-induc caspas activ stabl transfect wild-type lmp1 nasopharyng carcinoma cell line tw03 final us delet mutant lmp1 determin region lmp1 requir apoptosi potenti found amino acid 350-386 locat ctar2 domain respons sensit cell cisplatin conclud lmp1-depend potenti stress-induc apoptosi occur earli step apoptosi cascad upstream activ caspas-2 involv c-termin signal domain lmp1 find import ramif treatment ebv-associ malign epitheli origin includ nasopharyng carcinoma
tazaroten-induc gene tig1 tazaroten-induc gene tig3 retinoid acid target gene well candid tumor suppressor gene human cancer studi investig express tig1 tig3 nasopharyng carcinoma npc loss tig1 express found npc cell line xenograft wherea tig3 express npc sampl immort nasopharyng epitheli cell order elucid epigenet silenc tig1 npc methyl statu tig1 promot examin genom bisulfit sequenc methyl-specif pcr msp detect dens methyl tig1 5'cpg island tig1-neg npc cell line xenograft c666-1 cne1 cne2 hone1 x666 partial methyl observ npc cell line hk1 show dramat decreas tig1 express promot methyl absent tig1-express npc xenograft normal epitheli cell restor tig1 express unmethyl allel observ npc cell line 5-aza-2'-deoxycytidin treatment moreov methyl tig1 sequenc detect 90.7 primari npc tumor msp conclus result show tig1 express lost major npc cell line xenograft promot hypermethyl major mechan tig1 silenc furthermor frequent epigenet inactiv tig1 primari npc tumor impli plai import role npc tumorigenesi
opsoclonu-myoclonu syndrom om rare autoimmun neurolog disord poorli recogn undertr neuroblastoma found on half case becaus high incid spontan regress neuroblastoma unknown whether find tumor mean none defin demograph trend standard care first larg seri om 105 children recruit 13-year period retrospect questionnair survei children tumor differ littl viral-like prodrom neurolog symptom earliest neurolog symptom stagger fall lead misdiagnosi acut cerebel later symptom includ bodi jerk drool refus walk sit speech problem decreas muscl tone opsoclonu inabl sleep tumor resect alon provid adequ therapi most adrenocorticotrop hormon acth prednison intraven immunoglobulin us equal frequenc acth associ best earli respons on half children relaps residu behavior languag cognit problem occur major delai diagnosi week initi treatment week unaccept long
000 newli diagnos cancer patient expect advers event relat care year histor advers event medic relat two third thought prevent major error occur order write process priorit chang made joint pediatr program children's hospit boston dana-farber cancer institut initi templat order develop computer order entri system goal initi decreas error relat chemotherapi administr creat legibl complet clearli defin order set same time make order write review effici chemotherapi templat creat us consist format rigor multidisciplinari review process order set includ identif patient cycl chemotherapi given criteria necessari receiv chemotherapi chemotherapi order modif appropri support care order templat order set reduc duplic work effort significantli reduc number chang made order verif process order complet standard occur
increasingli trend deliv chemotherapi possibl outpati ambulatori set few studi explor set cancer care long wait time frequent link dissatisfact sever factor contribut lengthi wait time patient famili long registr process lag time associ obtain laboratori result time requir patient assess prepar chemotherapeut agent adequaci nurs resourc physic space constraint relat patient volum goal improv care deliveri outpati clinic fast-track system establish program plan includ establish patient elig criteria protocol treatment appropri interdepartment collabor develop commun plan famili staff negoti physic space alloc human resourc institut re-alloc exist resourc establish autonom nurs-manag chemotherapi clinic fast-track program enabl us exist resourc greater effici improv patient care safeti qualiti-of-life perspect includ program
pediatr nurs work acut care set serv religi cultur divers famili encount parent belief influenc treatment decis previou literatur describ complex situat lead emot distress strain relationship health care provid famili member ethnograph studi conduct investig impact parent treatment refus bedsid interact pediatr nurs parent twenti in-depth interview nurs conduct extens field note taken data collect emot feel associ possibl loss guardianship subsequ mandat treatment impact situat nurs' health stress level function statu explor three theme identifi interpret narr analysi transcript field note weather storm moral conflict close involv versu distanc retreat battl support opposit group find studi lead deeper understand complex ethic dilemma surround treatment refus pediatr
local therapi pancreat cancer microencapsul cyp2b1-produc cell ifosfamid show effect both primari tumor distant metastatas possibl repres consequ activ immun respons studi demonstr local tumor irradi lead activ intratumor lymphocyt infiltr aim studi investig efficaci combin therapi low-dose irradi ifosfamid cyp2b1-produc cell syngen pancreat cancer induc lewi-rat subcutan inocul dsl6a tumor cell microencapsul cyp2b1-produc cell inject peritumor 10--12 week tumor implant anim random group control nacl i.p ifosfamid mg/kg i.p 3x/week local irradi ifosfamid plu irradi tumor growth monitor week tumor infiltr cd4+ cd8+ nk-cell microvessel densiti prolifer rate investig immunohistochemistri cytokin plasma level tnf-alpha measur elisa seven anim group combin therapi show object respons therapi therapi ifosfamid radiat alon show respond respect mean tumor volum significantli reduc combin ifosfamid plu radiat therapi first week wherea monotherapi ifosfamid radiat significantli decreas tumor growth earliest week respect high plasma level tnf-alpha control group significantli reduc combin ifosfamid/irradi treatment lymphocyt infiltr tumor prolifer significantli differ group microvascular densiti significantli increas ifosfamid ifosfamid plu irradi therapi combin ifosfamid/cyp2b1-produc cell irradi show earlier therapeut effect growth rat pancreat cancer irradi ifosfamid alon evid late activ lymphocyt infiltr pcna-posit tumor cell
convent chemotherapeut drug us treatment cancer patient advanc stage yield limit benefit regard surviv time mention cure patient improv clinic outcom cancer agent aim novel molecular target requir colorect cancer caus hyperact wnt/beta-catenin signal pathwai result constitut beta-catenin mediat transactiv cell factor tcf -depend gene disrupt signal pathwai hold promis develop anti-cancer drug studi describ recent therapeut strategi interfer tumor growth block unrestrict activ wnt/beta-catenin pathwai antagonist becom lead compound anticanc therapeut includ establish drug applic area recombin biomolecul viru mediat select cell kill small molecul disrupt protein-protein interact
kaposi's sarcoma current most common tumor zimbabw purpos studi compar effect support care intervent approach name oral etoposid 3-drug combin radiotherapi us qualiti life qol primari measur success addit studi determin whether diseas-specif modul greater sensit group differ gener qol questionnair determin most pragmat approach treat epidem kaposi's sarcoma ek zimbabw histolog confirm hiv-posit patient kaposi's sarcoma random receiv support care support care plu radiotherapi oral etoposid 3-drug combin consist actinomycin-d vincristin bleomycin patient receiv antiretrovir therapi primari outcom qol measur function live index-cancer fli-c supplement kaposi's sarcoma modul ksm 1994-1999 495 ek patient accru 470 evalu 433 known dead lost follow-up still aliv group treat oral etoposid significantli better qol radiotherapi group total fli-c score adjust mean plu standard error 3-month +/- +/- 0.004 hardship +/- 0.4 +/- 0.4 0.001 social +/- 0.4 +/- 0.4 0.001 nausea +/- 0.4 +/- 0.4 0.002 subscal addit physic psycholog subscal etoposid group significantli better qol treatment group &lt 0.04 3-drug combin support care radiotherapi group differ significantli respect total fli-c score subscal group differ respect surviv oral etoposid therapi result better total fli-c qol score radiotherapi well etoposid result better physic psycholog subscal score radiotherapi 3-drug support care fund permit oral etoposid pragmat approach treat ek environ antiretrovir drug univers avail studi underscor valu undertak studi area diseas preval necess select appropri outcom measur
educ parent children cancer primari nurs respons pediatr oncolog survei us delphi techniqu conduct nurs attend children's oncolog group nurs workshop identifi prioriti educ topic pediatr oncolog nurs' perspect round survei nurs ask identifi prioriti educ topic topic spend most time teach parent twenti-four educ categori identifi 199 nurs respons sort categori frequenc tabul inform treatment most frequent cite prioriti bone marrow suppress bm second most import prioriti topic nurs spent most time teach round survei sent via e-mail 132 consent particip round nurs ask rate import categori round present random order time period diagnosi initi treatment mainten therapi nurs report differ teach prioriti across continuum treatment note teach end-of-life issu altern therapi rank low import across time point find us inform educ program materi develop parent children cancer
macrophag migrat inhibitori factor mif known proinflammatori cytokin well tumor growth regul posit neg effect mif tumor cell growth report exact role mif tumorigenesi remain ambigu examin express mif protein tumor specimen obtain head neck squamou cell carcinoma hnscc patient treat concurr chemoradiotherapi carboplatin 100 mg/m2 4-7 time everi week total radiat therapi dose 65-75 6.5-7.5 week determin whether mif level relat clinic outcom patient immunostain mif specif antibodi perform formalin-fix paraffin-embed specimen mif protein express variou extent tumor tissu specimen hnscc patient prognost analysi us kaplan-meier method regard mif express reveal patient mif-neg tumor wors prognosi compar mif express result studi suggest intratumor mif express prognost valu hnscc patient administ concurr chemoradiotherapi
biolog function metallothionein protein encod function isoform includ cell prolifer differenti apoptosi aim studi compar rel express level function mrna isoform three nasopharyng cancer npc cell line laryng carcinoma embryon lung cell line quantit real-time rt-pcr npc line exhibit express mt-2a transcript wherea mt-1e isoform express well differenti hk1 moder differenti tw01 poorli differenti cne2 cell interestingli tw01 hep-2 laryng cancer cell exhibit similar express profil both mt-1e mt-2a isoform detect level mrc-5 embryon lung fibroblast function studi mt-2a isoform down-regul express gene mt-2a antisens oligonucleotid cne2 cell show reduct cell viabil prolifer find provid valuabl inform search novel therapeut strategi npc
aphidicolin tetracycl diterpen antibiot produc cephalosporium aphidicola under investig anti-cancer drug becaus poor solubl water administ directli vivo system applic aphidicolin glycin aphidicolin gamma-cyclodextrin complex result tumour growth inhibit cure improv pharmacokinet liposom prepar aphidicolin develop test neuroblastoma-bear ukf-nb-3 mice load capac liposom limit 4.5 aphidicolin/kg bodi weight maximum aphidicolin dose appli liposom prepar approach comparison effect tumour growth exhibit aphidicolin liposom 4.5 aphidicolin/kg given consecut dai gamma-cyclodextrin inclus complex aphidicolin/kg reveal compar tumour growth inhibit aphidicolin concentr approxim 3-fold lower show liposom encapsul promis strategi improv system anti-cancer activ aphidicolin
survivin member inhibitor-of-apoptosi famili essenti protein regular mitosi involv anti-apoptot pathwai studi associ survivin express radiosensit describ tumor cell relationship p53 survivin regard radioresist remain clarifi order increas effect irradi two sarcoma cell line a-204 wt-p53 8-93 mt-p53 sirna appli knock down survivin express effect combin treatment sirna treatment irradi investig clonogen surviv assai measur activ caspas western blot hybrid survivin p53 morpholog analysi apoptosi survivin knock down caus radiosensit cell line a-204 wt-p53 enhanc factor 1.8 0.05 2.5 0.02 respect radiosensit found cell line 8-93 mt-p53 clonogen surviv analyz find support increas activ 5.2-fold caspas cell line a-204 wt-p53 cell line 8-93 mt-p53 combin treatment sirna irradi find suggest wt-p53-caspas pathwai import radiosensit induc target survivin impact futur gene therapeut treatment
trail tumor necrosi factor-relat apoptosi-induc ligand preferenti induc apoptosi cancer cell toxic normal cell trail plai import role host immun surveil tumor metastasi cathepsin mediat apoptosi activ regul inhibitor known cystatin examin trail-mediat cytotox rate clonal-relat primari metastat oral cancer cell correl express level trail receptor cathepsin cystatin two pair primari 686tu 101a metastat 686ln 101b cell line treat variou concentr 1000 ng/ml recombin human trail protein cell viabil apoptot rate determin both pair cell line primari cell reveal greater suscept trail metastat counterpart protein synthesi inhibitor cycloheximid markedli increas trail sensit cell line wherea cb-specif chemic inhibitor ca-074 markedli reduc sensit primari cell trail dna ladder m30 cytodeath immunodetect assai confirm trail-induc cell death apoptot process express level trail death dr4 dr5 decoi dcr1 dcr2 receptor differ primari metastat cell howev express level cystatin higher metastat cell respect primari cell wherea level remain unchang cathepsin mediat trail-induc apoptosi cell elev level cystatin metastat cell caus greater resist trail-induc apoptosi data suggest high express cystatin cell confer metastat phenotyp enhanc resist trail
base previou studi found ifnar2-1 short ifnalpha/beta receptor variant express pleomorph sarcoma cell decid determin rel level express ifnar2.1 versu longer form name ifnar2.2 differ pleomorph sarcoma cell relat respons interferon alpha treatment examin panel cell isol surgic specimen found ifnar2.1 prevail line analys gener show cell cycl arrest low level apoptosi ifnalpha treatment revers ratio i.e higher constitut level ifnar2.2 ifnar2.1 associ irrevers inhibit cell growth pronounc apoptosi impair tumour growth low- high-dose ifnalpha treatment nude mice inocul cell express predominantli ifnar2.1 assert effect cytokin vivo proteom analysi 120 signal compon growth arrest apoptot cell harbour higher level ifnar2.2 reveal engag canon jak/stat/isgf3-pathwai activ mitochodri apoptot pathwai potenti novel mechan cell cycl blockad unrel down-regul cyclin a/b interact/regul kinas result confirm domin neg role ifnar2.1 suggest rel endogen level two ifnalpha/beta receptor isoform dictat signal pathwai trigger ligand caus exclus cell cycl arrest induc program cell death paramet import clinic outcom ifnalpha treatment
apigenin common dietari flavonoid shown induc cell growth-inhibit cell cycl arrest cancer cell line on import effect apigenin increas stabil tumor suppressor p53 normal cell apigenin expect plai larg role cancer prevent modifi effect p53 protein howev mechan apigenin's effect p53-mutant cancer cell reveal yet assess influenc apigenin cell growth cell cycl p53-mutant cell line treatment apigenin result growth-inhibit g2/m phase arrest two p53-mutant cancer cell line ht-29 mg63 effect associ mark increas protein express p21/waf1 shown p21/waf1 mrna express markedli increas treatment apigenin dose- time-depend manner howev detect p21/waf1 promot activ treatment apigenin similarli promot activ pg13-luc p53-respons promot plasmid activ treatment apigenin p53 protein express result suggest p53-independ pathwai apigenin p53-mutant cell line induc p21/waf1 express growth-inhibit apigenin us chemoprevent agent wild-type p53 statu cancer mutant p53
tradit chines herbal medicin tcm centuri us diseas prevent treatment find us altern western cancer therapi panel tcm chose four compound repres two function class botan purifi plant flavin scutellarin circulatori stimul baicalin antipyret two extract purifi salvia miltiorrhiza sm-470 circulatori stimul camellia sinensi cam-300 antipyret examin anti-prolifer effect human breast cancer cell line mcf-7 t-47d four compound inhibit mcf-7 t-47d cell prolifer baicalin most potent inhibitor moreov combin compound differ class offer enhanc potenti therapeut benefit combin sm-470 scutellarin cam-300 baicalin augment inhibit cell prolifer synergist inhibitori effect mcf-7 cell prolifer observ sm-470 baicalin appli togeth contrast inhibit t-47d cell prolifer us same combin depend baicalin anti-prolif effect compound extend cancer type human head neck cancer epitheli cell line cal-27 fadu sensit four drug overal sm-470 cam-300 scutellarin baicalin inhibit prolifer human breast cancer cell cal-27 fadu cell differ potenc baicalin sm-470 combin produc addit effect suggest compound function differ mechan t-47d mcf-7 fadu cell us explor cellular molecular mechan action baicalin sm-470
human involucrin gene encod precursor keratinocyt cornifi layer strongli express respons differenti stimuli earlier studi suggest yy1 compon ap-1 famili particip silenc involucrin prolifer keratinocyt studi show overexpress yy1 c-jun repress transcript human involucrin gene multipli keratinocyt transient overexpress site-direct mutagenesi experi involucrin 5'-non-code region 5'-ncr confirm yy1 c-jun repress involucrin transcript repress involv distal zinc finger yy1 protein dna bind leucin zipper domain c-jun result protein pull-down experi consist hypothesi interact yy1 c-jun import mechan involucrin repress cotransfect yy1 modifi stimulatori function mutant c-jun protein independ dna bind capac suggest interact complex vivo addition c-jun protein level affect differenti stimuli indic import c-jun yy1 repress pathwai yy1 c-jun import role epiderm differenti neg regul human involucrin gene
found two polymorph posit l-myc transcript start site 9-base stretch posit l-myc utr exhibit strong linkag disequilibrium two haplotyp a-9g c-8g analyz whether both haplotyp utr l-myc gene approxim 200 long involv translat regul l-myc gene haplotyp utr insert renilla luciferas firefli luciferas gene construct bicistron vector transcrib singl mrna translat downstream cistron increas 70-100-fold co cell 7-10-fold hela cell compar control vector insert howev bicistron assai system both haplotyp l-myc utr show similar intern ribosom entri site ir activ stabl hairpin loop palindrom sequenc insert 5'-end bicistron mrna hairpin loop decreas activ upstream luciferas both co hela cell support presenc ir insert utr l-myc gene 5'-end report mrna c-8g show approxim 2-fold higher ir activ a-9g both co hela cell suggest two polymorph l-myc exon involv regul l-myc protein express
purpos investig synergist cytotox trail combin chemotherapeut agent a549 cell line systemat evalu cytotox trail alon trail combin cisplatin paclitaxel taxol actinomycin a549 cell line vitro vivo whether sensit correl express level trail receptor method investig cytotox trail alon synergist antitumor effect trail combin chemotherapeut agent a549 cell crystal violet stain fac vitro express level dr4 dr5 dcr1 dcr2 measur trail-treat chemotherapeut agent-treat a549 cell western blot growth inhibit tumor evalu term incid volum weight a549-implant nude mice model result chemotherapeut agent cisplatin 5.56 mug/ml taxol mug/ml actinomycin 9.26 83.3 750 ng/ml augment cytotox trail a549 cell line rang concentr trail 1.98-160 ng/ml vitro express level dr4 dr5 significantli differ express dcr2 slightli downregul express dcr1 detect non-treat trail-treat chemotherapeut agent-treat a549 cell rate tumor inhibit treatment trail alon mg/kg per dai daili dai trail/cisplatin mg/kg per dai trail daili dai 1.5 mg/kg per dai cisplatin daili dai 7-dai interv 28.3 76.8 tumor weight p&lt 0.05 trail alon versu control p&lt 0.05 trail/cisplatin versu cisplatin alon trail alon dai vivo conclus trail combin chemotherapeut agent cisplatin taxol actinomycin exert synergist antitumor effect a549 cell line vitro trail/cisplatin demonstr synergist antitumor effect vivo express level trail receptor suggest synergist effect trail combin chemotherapeut agent receptor level a549 cell line
parenter administr arsen trioxid recent recogn effect antineoplast therapi especi treatment acut promyelocyt leukemia efficaci toxic concentr-depend relat fraction differ arsen speci degre methyl studi arsen trioxid given parenter rabbit singl dose daili dose 0.2 0.6 1.5 mg/kg dai blood organ concentr arsen speci includ iii dimethylarsin acid dma monomethylarson acid mma studi dai singl-dose studi dai multipl dose studi dai revers studi iii major detect arsen speci blood pharmacokinet paramet total clearanc area under curv iii indic limit capac elimin iii dose 1.5 mg/kg same singl dose chronic multipl dose tissu dma found major metabolit concentr dma iii mma gener increas dose increas most signific dose 1.5 mg/kg howev normal tissu distribut iii kidnei dai dai nonlinear along decreas level iii increas level dma induc capac methyl iii dma chronic dose kidnei suggest tissu concentr dma highest lung liver normal tissu distribut liver dai nonlinear suggest limit elimin dma chronic high load iii tissu concentr iii dma mma bladder increas dramat chronic dose howev washout dai iii dma mma undetect bladder liver howev iii hair low level dma lung kidnei heart hair still detect conclus rabbit found similar pharmacolog profil singl dose chronic multipl dose parenter arsen trioxid limit metabol capac dose 1.5 mg/kg tissu accumul arsen speci mainli dma revers washout tissu-select potenti late toxic arsen trioxid organ signific tendenc arsen accumul low revers close monitor
background matrix metalloproteinas plai role process tissu invas metastasi degrad extracellular matrix inhibitor matrix metalloproteinas interest anticanc drug cp-471 358 matrix metalloproteinas inhibitor vitro demonstr strong inhibit matrix metalloproteinas drug administ oral food restrict studi design open-label phase studi perform patient advanc solid tumor assess safeti toler maxim toler dose mtd pharmacokinet cp-471 358 cp-471 358 dose studi 100 200 three time daili tid continu 100 200 tid dai follow 1-week treatment-free interv 150 twice daili bid continu result total patient treat studi median number cycl administ two rang on five myalgia arthralgia most frequent observ advers event patient observ dose level schedul except 150 bid continu dose level six patient nation cancer institut nci common toxic criteria ctc grade myalgia/arthralgia observ advers event consid dose-limit toxic dlt introduct 1-week treatment-free interv cycl effect occurr myalgia/arthralgia cessat treatment arthralgia/myalgia revers patient advers event observ fatigu increas liver enzym rare exceed ctc grade pharmacokinet analysi show target efficaci concentr achiev morn dose interv 150 bid 200 tid conclus dlt cp-471 358 myalgia arthralgia advers event observ treatment most matrix metalloproteinas inhibitor drug-free interv week unabl prevent occurr advers effect clearli repres limit potenti long-term us compound
3-year-old patient present anemia thrombocytopenia blast peripher blood bone marrow aspir reveal myelodysplast syndrom md mosaic abnorm femal karyotyp q42 p13.1 c[12]/ idem +21c[3]/ idem +21c +mar[7] obtain g-band metaphas unstimul bone marrow aspir cell cultur rule constitut abnorm perform cytogenet analysi patient's phytohemagglutinin-stimul peripher blood cultur skin fibroblast karyotyp q42 p13.1 found peripher lymphocyt analyz confirm constitut origin transloc addit cell two separ cultur skin fibroblast contain extra chromosom presenc two cell line multipl cultur indic patient true low-level mosaic trisomi becaus find monosomi marker chromosom trisomi clone conclud leukem clone aros hematopoiet precursor constitut trisomi possibl plai role develop md becaus acut myelogen leukemia aml md down syndrom distinct biolog clinic featur identif patient mild normal phenotyp aml/md popul fundament import clinic diagnosi manag
histon deacetylas inhibitor hdaci emerg promis class anticanc agent displai growth-inhibitori activ low toxic vivo studi examin effect sodium butyr nab trichostatin tsa growth human bladder carcinoma cell line cultur tsa growth um-uc-3 human bladder xenograft nude mice nab tsa suppress growth bladder cell line millimolar 1.5-4.3 micromolar 0.03-0.33 microm concentr respect induc concentr-depend cell death bladder carcinoma cell experiment panel displai phenotyp late-stage bladder lesion express n-cadherin absenc e-cadherin accompani low level plakoglobin express exposur cell hdaci result upregul plakoglobin chang e-cadherin express 2-hr exposur tsa minim time requir upregul plakoglobin cell downregul baselin level occur drug remov mice bear um-uc-3 bladder xenograft tsa 500 microg/kg/dai caus suppress tumor growth compar mice receiv vehicl alon reduct mean final tumor volum record both bladder xenograft model detect toxic result suggest tsa inhibit bladder carcinoma cell growth us rel nontox agent consider treatment late-stage bladder tumor
background waldenstrm's macroglobulinemia cd20 express b-cell malign repres patholog diagnosi igm secret lymphoplasmacyt lymphoma major respons rate report most studi standard dose rituximab i.e weekli infus 375 mg/m /week method effort increas rituximab activ extend dose schedul emploi two set four 375 mg/m /week infus week 1-4 12-16 evalu express complement resist antigen cd46 cd55 cd59 evalu tumor cell pre- post-therapi determin impact respons result twenti-nine patient enrol patient complet intend therapi intent treat analysi 48.3 patient achiev partial respons 17.2 patient achiev minor respons respons observ 18/24 patient serum igm level &lt 6000 mg/dl patient level 6000 mg/dl 0.03 median time best respons month respond patient progress median follow-up month differ baselin express complement resist antigen cd46 cd55 cd59 observ among respond non-respond patient post-therapi cd55 express higher non-respond patient 0.002 conclus data show extend rituximab therapi activ lead major respons standard dose rituximab patient serum igm level &lt 6000 mg/dl like benefit extend rituximab therapi
background result second-line chemotherapi patient extragonad non-seminomat germ cell tumor nsgct appear inferior result testicular nsgct patient retroperiton nsgct achiev compar long-term surviv rate salvag rate patient mediastin primari conduct retrospect analysi patient mediastin retroperiton nsgct treat second-line high-dose chemotherapi hdct regist european group blood marrow transplant ebmt patient method 1987 1999 regist patient retroperiton mediastin primari nsgct median ag year rang 18-60 treat second-line hdct receiv cisplatin-contain chemotherapi first-line treatment result toxic death occur three case median follow-up month rang 14-114 18/59 patient continu diseas-free three patient diseas recurr hdct on patient achiev diseas-free statu chemotherapi surgeri total patient current diseas-free sixteen patient retroperiton nsgct three patient mediastin nsgct current aliv diseas-free conclus second-line hdct repres possibl option patient retroperiton primari nsgct salvag strategi need patient mediastin nsgct
object aim studi evalu acut long-term morbid recurr rate overal surviv patient multipl groin lymph node metastas treat postop chemotherapi method patient affect figo stage iii iva ivb pelvic lymph node submit surgeri treat four cycl cisplatin 100 mg/m given dai apart toxic overal diseas-free surviv evalu result fourteen patient evalu median patient ag rang 48-82 median perform statu 0-2 patient complet treatment treatment-relat death occur two patient suffer grade neutropenia chemotherapi three patient suffer long-term sever lymphedema four patient suffer diseas recurr three patient subject surgeri sever postop complic two latter patient still aliv median follow-up 57.5 month rang 23-79 month actuari 3-year overal surviv progress-free surviv respect conclus patient affect vulvar cancer multipl lymph node metastas radic surgeri follow chemotherapi feasibl strategi accept short- long-term complic rate result term overal surviv diseas-free surviv promis furthermor due absenc local long-term tissu toxic strategi allow physician surgic treat region lymph node recurr safe
dihydropyrimidin dehydrogenas dpd rate-limit enzym 5-fluorouracil 5-fu catabol aim studi evalu prognost valu dpd express correl dpd express efficaci 5-fu retrospect analysi dpd express perform immunohistochem 103 patient oral squamou cell carcinoma oscc stain intens dpd express degre heterogen dpd express categor express dpd correl lymph node metastasi mode invas differenti express dpd independ signific factor surviv outcom predict convent clinic factor furthermor heterogen express dpd effect homogen express dpd neoplast cell evalu patient treat chemotherapi includ tegafur/uracil uft express dpd independ predictor clinic outcom furthermor heterogen dpd express clue predict sensit 5-fu patient oscc
human tongu well-differenti squamou carcinoma cell line scc-25 show fa-depend apoptosi treatment carboplatin cbdca fadd markedli up-regul cbdca result induct apoptosi fap-1 antiapoptot tyrosin phosphatas express cytosol block transduct death signal fa downstream studi show etodolac select cyclo-oxygenas-2 inhibitor enhanc cbdca-induc apoptosi scc-25 etodolac alon induc apoptosi combin cbdca etodolac significantli decreas fap-1 express both protein mrna level etodolac inhibit fap-1 express result indic etodolac combin cbdca enhanc action anticanc drug through suppress fap-1 express
object measur morbid vaso-occlus crise voc sickl cell diseas us nation hospit discharg databas kid' inpati databas kid determin number hospit hospit length stai lo ag procedur nation weight hospit discharg voc children sickl cell diseas analyz us data 500 hospit healthcar cost util project hcup kid number discharg hospit lo ag group analyz multipl linear regress perform analyz effect ag hospit lo result 271 hospit discharg children sickl cell diseas voc mean ag time admiss 10.6 5.38 year male overal averag lo 4.4 dai differ number hospit discharg ag group &lt 0.001 addit differ lo ag group &lt 0.0001 control potenti confound older ag associ longer lo &lt 0.0001 conclus older children sickl cell diseas voc increas hospit longer lo ag effect consid measur effect intervent hospit util children
report two case viscer larva migran vlm syndrom toxocara children biolog present unusu character persist secondari thrombocytosi 000 mimick essenti thrombocythemia variabl hypereosinophilia syndrom both children non-specif symptom includ abdomin pain skin rash fever diagnosi confirm serolog children treat thiabendazol albendazol result normal eosinophil platelet count
recent studi demonstr major influx transport ctr1 regul tumor cell uptak cisplatin ddp carboplatin cbdca oxaliplatin l-ohp two efflux transport atp7a atp7b regul efflux drug evid concept platinum drug enter cell distribut variou subcellular compart via transport evolv manag homeostasi includ demonstr bidirect cross-resist cell select resist drug parallel chang transport drug resist cell alter cytotox sensit drug accumul cell transfect transport alter express transport drug-resist tumor appreci role transport develop resist ddp cbdca l-ohp offer novel insight strategi prevent revers resist import famili anticanc drug
widespread clinic us platinum compound cancer chemotherapi prompt search platinum agent search platinum agent novel profil activ us cluster imag map compar algorithm numer method analyz platinum compound submit nation cancer institut's anticanc drug screen test screen's divers human cancer cell line nci-60 total 107 platinum compound data adequ cluster group character distinct activ profil cell line group except mix on found characterist chemic structur well four group subject analysi mean graph represent averag activ profil differ group serv highlight similar differ identifi compound retain activ set resist clinic us platinum compound determin activ level compound repres differ activ-structur group cisplatin oxaliplatin-resist ovarian cancer cell line compound retain activ resist cell provid evid differ cisplatin oxaliplatin select activ variou nci-60 cell type suscept mechan resist platinum compound gener classifi alkyl agent compar pattern activ repres alkyl agent nci-60 growth rate profil 1582 molecular marker nci-60 cell much analysi remain done absenc definit biolog interpret molecular predictor activ consist idea platinum compound multipl intracellular target cell multipl mechan resist
purpos review addit have genet caus cancer consid epigenet diseas main epigenet modif dna methyl pattern aberr dna methyl recogn common hallmark human tumor on most characterist featur inactiv tumor-suppressor gene cpg-island hypermethyl cpg island locat promot region site among other target dna-demethyl agent promis chemotherapeut drug focu articl recent find four excit aspect recent arisen forefront advanc field first develop compound dna-demethyl capac toxic exampl procain administ oral exampl zebularin second better knowledg molecular mechan underli action drug particular gene genom third establish reliabl techniqu measur effect drug clinic sampl high-perform capillari electrophoresi fourth decis effort clinic trial merit approv 5-azacytidin u.s food drug administr treatment myelodysplast syndrom summari dawn era epigenet drug will import weapon arsen war cancer hematolog malign provid promis start point studi will sure extend solid tumor howev need continu research develop specif dna-demethyl agent understand biolog effect determin whether successfulli combin epigenet drug inhibitor histon deacetylas classic chemotherapi compound
locoregion recurr remain major obstacl achiev cure local advanc head neck cancer despit multimod therapi multipl studi report low hemoglobin hgb befor radiat therapi import risk factor poor locoregion diseas control surviv anemia common head neck cancer popul suspect contribut intratumor hypoxia result radioresist have low hgb level shown detriment unclear exactli threshold low hgb studi area us threshold rang 9-14.5 g/dl qualiti-of-life studi suggest correct moder sever anemia result signific gain optim hgb level improv outcom vari across tumor type area requir evalu howev correct anemia worthwhil strategi radiat oncologist improv local control surviv articl review impact anemia outcom radiotherapi head neck cancer
bisphosphon bp stabl pyrophosph analog current us treatment patient metastat bone diseas known affect bone resorpt reduc osteoclast activ us drug adjuv therapi current under investig report effect bp tumor cell apoptosi preclin model recent evid suggest bp affect tumor cell invas vitro compon process adhes migrat degrad through mechan includ inhibit prenyl intracellular small gtpase ra rho effect potenti enhanc through co-administr chemotherapi agent both synergist addit effect describ vitro review discuss preclin evid potenti us bp cytotox drug inhibit tumor cell invas kei process cancer progress
cytotox platinum compound pt1 9-dimethyl-4 7-diphenyl-1 10-phenanthrolinedichloroplatin six polyoxometal pom1-6 two neuroblastoma cell line shep-sf kcn ew's sarcoma cell line cado-es-1 studi cisplatin [ci-diamminedichloroplatinum carboplatin [ci-diammin cyclobutanedicarboxylato platinum us refer agent us mtt test cytotox ld50 lethal dose compound measur differ concentr exposur ld50 data platinum-contain substanc rang 4.47 1.91 shep-sf cell line displai highest sensit cisplatin novel platinum agent pt1 similar cytotox effect refer agent cisplatin both cisplatin pt1 cytotox carboplatin pom reduc cell viabil compar untreat cell concentr 8.4 3.47 pom1 ch3 4n]2na6.5 nh4 2[snii1.5 wo2 0.5 wo2 sbw9o33 32h2o most effect polyoxoanion mean ld50 valu 8.83 three cell line test cado-es-1 kcn cell pom1 found effect platinum compound cisplatin carboplatin pt1
regul tissu homeostasi crucial diseas prevent cell divis cell cycl arrest differenti apoptosi tightli control order maintain homeostasi retino acid histon deacetylas inhibitor hdaci profound effect process critic regul homeostasi consequ histon deacetylas inhibitor current test clinic trial varieti cancer unfortun littl known overal affect compound cellular gene express decid compar effect all-tran retino acid atra particular hdaci-trichostatin tsa -on embryon carcinoma cell line us gene chip analysi focus particular attent gene differenti affect compound paramet establish studi 116 488 gene examin similarli regul atra tsa posit neg addit gene affect on compound gene actual invers regul gene set invers regul atra tsa includ sever import pattern gene well crucial tumor suppressor/promot transform growth factor beta tgfbeta1 promot analysi suggest motif regul on set gene studi provid first comprehens comparison global gene express cell affect atra hdac inhibitor tsa reveal target atra hdac inhibitor identifi regulatori motif demonstr atra hdac inhibitor act synergist gene express examin particular question regard concurr clinic applic
unlik postmitot cell death direct premitot apoptosi diminish risk clonal select allow elimin slowli grow cancer cell studi character abil induc premitot apoptosi irofulven hydroxymethylacylfulven novel alkyl drug target cellular dna protein irofulven effect examin hela-deriv bh2 cancer cell condit overexpress antiapoptot bcl-2 cell synchron earli exposur irofulven cell origin earli accumul late remain earli phase 0.5 2.5 mum drug respect drug treatment cell cohort prevent entri phase signific apoptosi detect base appear sub-g particl cell dna strand break both cohort apoptot cell mostli recruit border cohort phase earli cohort cell cycl apoptot effect margin affect bcl-2 overexpress similar result obtain irofulven-treat synchron cultur leukem cem cell collect observ indic irofulven-treat cell becom commit death earli neither activ dna replic nor travers through mitosi necessari irofulven-induc cell death abil promot direct premitot apoptosi like plai role consist potent apoptot effect irofulven abil caus tumor regress vivo
multipl myeloma multi-process diseas differ process respons reduc sensit chemotherapi radiotherapi henc relaps refractori natur multipl myeloma emphasi place hypothesi myeloma cell growth inhibit apoptosi drug resist depend immunomodulatori cytokin il-6 pro-angiogen factor vegf addit anti-angiogen effect immunomodulatori properti thalidomid make possibl therapi patient advanc multipl myeloma lead clinic develop number immunomodulatori thalidomid analogu imid potent side effect parent drug thalidomid august issu journal clinic oncolog schei suggest imid cc-4047 mayb efficaci due t-cell co-stimul safe patient relaps refractori multipl myeloma articl demonstr support role imid immunomodulatori adjuv therapi
object multicent phase studi design determin activ toler gemcitabin raltitrex advanc pancreat adenocarcinoma patient method thirti-three chemona patient measur diseas receiv tomgem regimen consist raltitrex mg/m min follow gemcitabin 000 mg/m min dai gemcitabin alon 000 mg/m dai repeat dai result thirti-three patient median ag local advanc/metastat diseas 5/28 enrol total number cycl administ 173 median partial respons confirm stabl diseas week &lt week progress diseas respons rate 30.3 14-46 clinic benefit observ 8/30 patient assess median durat respons 9.1 month nation cancer institut common toxic criteria grade iii neutropenia/thrombocytopenia observ patient respect relev nonhematolog toxic grade iii-iv rare on toxic death observ median time progress 2.8 month on-year surviv median surviv 4.7 month conclus data suggest combin raltitrex/gemcitabin conveni regimen accept toxic activ advanc pancreat cancer
object order elucid effect radiat centrosom hyperamplif examin centrosom duplic cycl kk47 bladder cancer cell irradi method kk47 cell irradi variou dose radiat examin immunostain gamma-tubulin result control cell contain on two centrosom mitot cell displai typic bipolar spindl centrosom replic cycl well regul kk47 twenti-four hour 5-gy irradi approxim irradi cell arrest phase irradi 56.9 cell contain two centrosom laser scan cytometri perform irradi show two pathwai unequ distribut chromosom daughter cell failur undergo cytokinesi result polyploidi mitot collect m-phase cell divid cell micronuclei polyploid cell fluoresc situ hybrid analysi show clear sign chromosom instabl cin irradi present studi two major find continu duplic centrosom occur cell cycl-arrest cell irradi lead centrosom amplif cytokinesi failur due aberr mitot spindl format caus presenc amplifi centrosom abnorm mitosi amplifi centrosom detect accumul g2/m popul irradi show amplif centrosom caus failur undergo cytokinesi rather abnorm mitosi result amplif centrosom lead cytokinesi block conclus result suggest critic event lead cin exposur radiat
liposom close vesicular structur consist on lipid bilay gener great deal interest drug deliveri vehicl particular investig abil improv deliveri chemotherapeut agent tumor effort increas therapeut efficaci decreas toxic normal cell develop liposom chemotherapeut agent past hinder primarili rapid uptak liposom reticuloendotheli system numer strategi seek exploit avoid phenomenon us result sever liposom chemotherapeut agent avail clinic stealth novel liposom system coat polyethylen glycol avoid uptak reticuloendotheli system improv drug deliveri tumor decreas toxic pegyl liposom doxorubicin doxil/caelyx [pld] deliveri system encapsul doxorubicin polyethylen glycol-coat liposom lead promis applic well-establish drug liposom-encapsul doxorubicin citrat complex myocet [npld] anoth liposom deliveri system doxorubicin lack polyethylen glycol coat result much shorter circul time pld daunorubicin citrat liposom daunoxom [dnx] contain daunorubicin encapsul smaller liposom differ lipid composit circul time pld npld articl review advantag liposom deliveri system gener diverg approach taken develop agent
encapsul doxorubicin polyethylen glycol-coat liposom doxil/caelyx [pld] develop enhanc safeti efficaci convent doxorubicin liposom alter pharmacolog pharmacokinet paramet convent doxorubicin drug deliveri tumor enhanc toxic normal associ convent doxorubicin decreas anim human pharmacokinet advantag pld includ increas area under plasma concentr-time curv longer distribut half-life smaller volum distribut reduc clearanc preclin model pld produc remiss cure cancer includ tumor breast lung ovari prostat colon bladder pancrea well lymphoma sarcoma myeloma found effect adjuv therapi addit found cross blood-brain barrier induc remiss tumor central nervou system increas potenc convent doxorubicin observ contrast convent doxorubicin pld equal effect low- high-growth fraction tumor combin pld vincristin trastuzumab result addit effect possibl synergi pld appear overcom multidrug resist possibl result increas intracellular concentr interact liposom p-glycoprotein function basi pharmacokinet preclin studi pld alon part combin therapi potenti applic treat varieti cancer
convent chemotherapi regimen treatment advanc kaposi's sarcoma show limit efficaci consider toxic liposom anthracyclin potenti util includ pegyl liposom doxorubicin doxil/caelyx [pld] daunorubicin citrat liposom daunoxom [dnx] nonpegyl liposom doxorubicin myocet [npld] preclin data show pegyl liposom accumul preferenti highli vascular lesion random clinic trial pld induc higher respons rate convent combin chemotherapi regimen bleomycin vincristin convent doxorubicin abv dnx produc respons rate compar abv npld compar convent chemotherapi pld dnx associ toxic compar abv includ alopecia fewer gastrointestin neurolog side effect grade 3/4 myelosuppress common both pld dnx stomat infus reaction occur pld treatment hand-foot syndrom rel infrequ dose schedul us health-relat qualiti life improv sever domain patient treat pld dnx compar abv
preclin studi establish pharmacolog advantag liposom anthracyclin includ pharmacokinet profil bolu dose resembl continu infus convent anthracyclin increas drug concentr tumor cell compar surround tissu reduc toxic rel convent anthracyclin treatment base studi phase phase clinic trial conduct assess safeti potenti activ liposom anthracyclin manag both solid hematolog tumor studi provid valuabl insight safeti pegyl liposom doxorubicin doxil/caelyx [pld] nonpegyl liposom doxorubicin myocet [npld] liposom daunorubicin daunoxom [dnx] rang dose singl-agent therapi combin cytotox agent liposom anthracyclin develop well toler activ remain elucid clinic trial avail data suggest liposom anthracyclin activ tumor type known sensit convent anthracyclin potenti tumor typic anthracyclin-resist despit avail clinic data wide varieti tumor type patient popul studi liposom anthracyclin therapi need fulli establish safeti efficaci dose treatment patient
patient multipl myeloma typic respond initi chemotherapi almost patient relaps median surviv approxim year combin vincristin convent doxorubicin oral dexamethason vad reduc-dose dexamethason vad provid rapid respons patient us limit toxic concern inconveni continu infus cycl us pegyl liposom doxorubicin doxil/caelyx [pld] vincristin intraven inject oral dexamethason dvd reduc-dose dexamethason dvd safe effect manag newli diagnos relaps/refractori control trial show dvd/dvd least effect vad/vad treatment dvd associ neutropenia alopecia addit requir fewer dai hospit clinic drug administr dvd therapi report associ antiangiogen effect observ vad anoth liposom anthracyclin liposom daunorubicin daunoxom [dnx] investig preliminari data suggest safe effect studi compar regimen report earli result ongo trial suggest ad thalidomid bortezomib immun modul pld-base chemotherapi improv efficaci
convent anthracyclin activ tumor type cardiotox relat cumul dose limit us particularli problemat patient risk factor increas toxic receiv anthracyclin past receiv cardiotox agent preclin studi determin encapsul convent anthracyclin liposom reduc incid sever cumul dose-relat cardiomyopathi preserv antitumor activ control clinic trial risk cardiotox significantli lower nonpegyl liposom doxorubicin myocet [npld] substitut convent doxorubicin risk significantli differ npld us place convent epirubicin direct comparison convent doxorubicin therapi show compar efficaci significantli lower risk cardiotox pegyl liposom doxorubicin doxil/caelyx [pld] therapi retrospect prospect trial identifi maximum cardiac safe dose pld despit us cumul dose exceed 000 mg/m2 patient liposom daunorubicin daunoxom [dnx] associ lower risk cardiotox convent anthracyclin compar trial avail respect combin chemotherapi earli result clinic trial suggest combin trastuzumab taxan npld pld instead convent anthracyclin significantli reduc cardiotox risk reduc chemotherapeut efficaci result eagerli await ongo control trial cardiac safeti long-term liposom anthracyclin therapi alon combin potenti cardiotox agent
nurs care patient receiv chemotherapi includ patient educ drug administr well ongo assess earli identif intervent side effect two liposom anthracyclin avail unit state pegyl liposom doxorubicin doxil/caelyx [pld] liposom daunorubicin daunoxom [dnx] becaus uniqu liposom formul administr toxic profil agent differ convent anthracyclin well common sever toxic convent anthracyclin treatment nausea/vomit alopecia neutropenia frequent sever liposom anthracyclin treatment cumul-dose cardiotox rare particularli pld therapi dose-relat advers event liposom anthracyclin therapi includ stomat neutropenia frequent dose pld associ hand-foot syndrom ongo nurs assess patient educ adjust dose dose-schedul reduc sever frequenc toxic nurs awar uniqu characterist liposom anthracyclin therapi provid optim patient educ nurs care
nanoscal drug deliveri system includ liposom polym nanoparticl provid potenti solut improv cancer therapeut drug deliveri system liposom-base agent particularli liposom anthracyclin greatest impact oncolog date current liposom drug evolv number design strategi improv biodistribut free drug reticuloendotheli system-target formul significantli reduc system exposur high peak level free drug facilit target tumor passiv physiolog target drug tumor achiev us long-circul liposom includ pure lipid system well surfac-modifi formul design resist recognit uptak reticuloendotheli system cell latter repres pegyl stealth liposom circul dai stabl construct slowli extravas neoangiogen vessel tumor provid degre passiv target tumor tissu futur liposom therapeut build valid design well pharmacolog insight mechan deliveri exampl camptothecin analogu anti-angiogenesi agent antisens oligonucleotid repres ration candid deliveri highli stabil long-circul liposom agent pegyl liposom deliveri offer improv chemic stabil encapsul drug enhanc accumul tumor prolong drug exposur true molecular target achiev us liposom link ligand monoclon antibodi fragment direct cancer-associ antigen immunoliposom combin antibodi-mediat tumor recognit liposom deliveri design target cell intern provid intracellular drug releas recent advanc immunoliposom design includ rapid select phage antibodi-deriv scfv target method conjug ligand exist food drug administr-approv liposom drug pegyl liposom doxorubicin doxil/caelxi [pld] immunoliposom consist novel anti-her2 scfv conjug pld current develop select bind intern her2-overexpress tumor cell modular organ immunoliposom technolog enabl combinatori approach repertoir monoclon antibodi fragment us conjunct seri liposom drug yield gener molecularli target agent
purpos evalu abil d-sacchar acid 1.4-lacton sal beta-glucuronidas inhibitor prevent irinotecan hydrochlorid cpt-11 induc mucos damag caus diarrhea rat method wistar rat divid six group three anim administ 1.0 isoton solut intraperiton onc daili three consecut dai respect six dai seri follow dai 1-3 salin dai 1-3 200 cpt-11/m2 dai rel first administr cpt-11 mg/ml sal dai 1-3 200 cpt-11/m2 dai rel first administr cpt-11 mg/ml sal dai 1-3 addit 200 cpt-11/m2 dai 1-3 200 cpt-11/m2 0.5 mg/0.5 sal dai rel first administr cpt-11 mg/ml sal dai 1-3 200 cpt-11/m2 lumin mucosa damag small intestin detect histolog intraperiton applic peptidas activ proxim jejunum measur us situ perfus model result intraperiton cpt-11 treatment us convent histolog paraffin section observ sever mucos damag reflect decreas villi/crypt ratio increas apoptot cell well increas mitot figur crypt region concomit increas lymphat infiltr mucosa cpt-11 treat rat damag pattern clearli reduc co-treatment beta-glucuronidas inhibitor sal independ treatment schedul contrast expect base previou report intraperiton applic cpt-11 alon combin sal caus signific differ lumin enzym liber comparison control situ perfus assai conclus beta-glucuronidas inhibitor sal abl significantli reduc cpt-11-induc mucos damag small intestin rat observ soon clinic impact treatment patient cpt-11
aim investig therapeut effect lycium barbarum polysaccharid lbp mitomycin mmc -induc myelosuppress mice method mice intraven inject mmc 150 mg/kg two consecut dai dai dai produc sever myelosuppress treat s.c inject lbp 100 200 mg/kg/dai dai blood sampl collect tail vein mice dai peripher white blood cell wbc red blood cell rbc hemoglobin hgb platelet count plt monitor result lbp 100 mg/kg lbp-l dai lbp 200 mg/kg lbp-h dai significantli amelior decreas peripher rbc hgb hematocrit hct myelosuppress mice compar control lbp-l dai dai lbp-h dai significantli enhanc peripher plt recoveri myelosuppress mice compar control lbp-h dai significantli inhibit increas mean platelet volum mpv myelosuppress mice compar control lbp show obvious effect neutropenia induc mice mmc conclus lbp effect peripher rbc plt recoveri mmc-induc myelosuppress mice
background extent commun skill train cst american oncolog fellowship program unknown method survei sent program director medic oncolog radiat oncolog gynecolog oncolog surgic oncolog train program regard presenc method cst program attitud mandatori cst attitud mandatori assess commun skill compet prerequisit specialti certif result third program contain form cst surgic oncolog program particularli lack lack faculti time cite major barrier implement cst major program director support mandatori cst core compet requir certif conclus current defici cst american oncolog fellowship train given import commun skill provis high-qualiti cancer care initi address defici prioriti
concurr chemotherapi radiat improv outcom patient present local advanc squamou cell carcinoma head neck scchn improv cost increas treatment-relat toxic previous report result phase trial examin role concurr carboplatin paclitaxel daili radiotherapi scchn attempt decreas side effect conduct prospect phase trial evalu role amifostin ethyol medimmun oncolog inc gaithersburg patient treat concurr chemort scheme april 2002 septemb 2004 patient stage iii-iv scchn enrol prospect phase trial treatment consist daili deliv 70.2 1.8 gy/fx amifostin 500 &lt hour befor concurr weekli carboplatin 100 mg/m2 paclitaxel mg/m2 median ag 58.5 year rang year male femal ratio caucasian versu /39 tumor characterist base histolog primari cancer oropharynx 55.6 supraglott larynx 16.7 hypopharynx 16.7 oral caviti 5.6 unknown primari 5.6 patient present local advanc unresect diseas 27.8 advanc nodal diseas n2b-n3 toxic measur weekli treatment follow-up visit diseas respons therapi determin month complet therapi seventeen patient evalu respons surviv month complet eighti-four percent complet prescrib radiat treatment patient receiv six cycl chemotherapi median number miss chemotherapi cycl 1.5 rang cycl fifti-six percent patient receiv prescrib amifostin dose chemort-relat toxic most common reason withhold dose median dose miss amifostin three rang dose grade toxic associ therapi mucos dysphagia patient dehydr xerostomia dermat patient experienc grade leukopenia grade 3/4 neutropenia develop /13 grade 4/5 nonhematolog toxic encount forti percent patient complet unschedul treatment break secondari treatment-relat toxic median treatment-break time dai rang dai clinic complet respons both primari site diseas neck achiev patient month complet weekli carboplatin paclitaxel administ concurr definit daili amifostin well toler patient complet therapi accept toxic addit amifostin appear decreas treatment-relat toxic impact efficaci
standard convent radiat therapi advanc head neck tumor typic involv administ high radiat dose major salivari gland bilater most case caus mark reduct oral saliva output xerostomia on most preval late side effect radiat head neck malign patient cite major caus decreas qualiti life degre xerostomia report depend radiat dose volum salivari gland irradi sever studi show dose-volum-respons relationship salivari gland suggest possibl signific improv saliva product postradi well qualiti life radiat techniqu spare salivari gland grow bodi literatur support premis intens-modul radiat therapi imrt allow irradi tumor target head neck spare substanti portion salivari gland earli clinic experi shown substanti spare salivari flow imrt suggest least equal tumor control improv xerostomia compar patient receiv standard radiat techniqu hypothes addit radiat protector amifostin ethyol medimmun inc gaithersburg improv salivari function obtain imrt alon test hypothesi initi pilot clinic trial compar unstimul stimul salivari flow rate month year imrt amifostin histor control treat imrt alon twenti-seven patient accru onto trial toxic complianc data report herein
intens modul radiat therapi imrt allow rel parotid salivari gland spare patient undergo treatment head neck squamou cell cancer reliabl spare submandibular gland cytoprotect amifostin ethyol medimmun inc gaithersburg shown decreas rate acut late xerostomia patient undergo radiat therapi head neck squamou cell cancer addit amifostin imrt augment parotid salivari spare add submandibular/sublingu minor salivari gland spare result greater salivari flow rate physiolog saliva elig patient includ slate receiv definit imrt earli oropharynx cancer postop both chemotherapi advanc cancer includ favor favor exophyt n0-2b small volum oropharynx cancer receiv bilater neck postop patient nodal metastas primari perineur invas lymphovascular invas will elig patient will receiv fraction clinic target volum ctv will receiv ctv2 will receiv ctv3 will receiv mean dose goal parotid gland patient will receiv fix-dose amifostin 500 subcutan minut befor radiat fraction subject xerostomia questionnair will administ whole mouth individu major salivari gland stimul unstimul saliva will collect befor therapi week month xerostomia outcom will correl salivari dose volum histogram data accrual yet result studi will give indic object subject benefit combin imrt physic parotid salivari spare amifostin chemic cytoprotect combin salivari gland spare reduct rate xerostomia patient undergo imrt head neck squamou cell cancer
dry mouth xerostomia on most common complaint radiat therapi head neck cancer notabl caus irrepar damag salivari gland increas risk sever long-term oral pharyng disord sever strategi treatment head neck cancer develop prevent rt-induc salivari dysfunct provid definit oncolog therapi includ salivari-spare cytoprotect amifostin combin therapi high-dose-rate intraop extern beam plu cytoprotect salivari gland surgic transfer gene therapi futur research incorpor biolog pharmacolog technolog advanc optim therapeut ratio minim advers oral sequela warrant
amifostin ethyol medimmun inc gaithersburg cytoprotect radioprotect agent normal tissu deleteri effect chemotherapeut agent ioniz radiat compil uniqu databas meta-analysi aim address controversi concept tumor protect propos meta-analysi surviv outcom base individu patient data will us literatur-base meta-analys becaus superior reliabl longer follow-up patient data will possibl studi effect amifostin differ tumor type
platinum compound long us cancer chemotherapi understand biochemistri specif activ agent remain focu ongo research particularli regard next-gener platinum agent review will examin current knowledg recent studi molecular mechan platinum dna damag repair includ novel platinum dna target gene express associ platinum dna damag will explor well mechan platinum-drug deliveri drug resist futur direct develop novel platinum agent
recent experiment data suggest possibl us opioid combin improv analgesia cancer patient rapid opioid escal due worsen pain condit develop toler critic phase condit associ neg prognosi aim studi assess effect ad second opioid low dose patient poor analges benefit dose escal fourteen patient receiv strong opioid increas dosag 100 week unsuccessfulli randomli chosen add second opioid first us initi equival dosag previou therapi dose second opioid chang accord clinic situat obtain accept pain control minim advers effect pain symptom associ opioid therapi assess opioid escal index oei calcul weekli interv oei significantli decreas ad second opioid trend maintain week similarli pain intens significantli improv maintain accept level week second opioid induc signific opioid-relat advers effect opioid combin abl break opioid escal patient pain syndrom poor respons previou opioid allow regain analgesia regardless opioid combin us preliminari observ confirm studi
goal work goal studi examin associ exercis qualiti life qol multipl myeloma cancer survivor patient method us retrospect design 156 multipl myeloma cancer survivor mail questionnair assess self-report exercis behavior three period prediagnosi activ treatment off-treatment qol main result respons rate 88/ 156 descript analys indic 6.8 20.4 survivor met nation exercis guidelin activ off-treatment period respect exercis activ treatment off-treatment posit associ overal qol subdomain qol p&lt 0.05 except physic wellb conclus low percentag multipl myeloma cancer survivor exercis regularli activ off-treatment period survivor report exercis period report higher qol find suggest random control trial warrant
object clinic studi impli -epigallocatechin-3-gallat egcg main ingredi green tea catechin chemoprevent action cancer suppress prolifer cancer cell howev report chemoprevent effect renal cancer previous determin renal carcinogen suppress gap junction intercellular commun gjic renal epitheli cell studi investig effect egcg gjic renal epitheli cell treat renal carcinogen materi method mardin-darbi canin kidnei mdck cell us determin protect effect egcg dimethylnitrosamin-induc alter gjic connexin maximum concentr egcg determin lactat dehydrogenas assai method scrape-load dye transfer method us assess express cellular local phosphoryl statu determin western blot analysi result optim noncytotox concentr egcg determin microg/ml level gjic express markedli decreas mdck cell expos dimethylnitrosamin 12-h pretreat egcg greatli amelior gjic-inhibitori effect dimethylnitrosamin conclus result suggest preserv gjic indic chemoprevent effect green tea renal epitheli cell treat renal carcinogen vitro
seri 4triazino[4 3-a]indol prepar good yield react 2-diazo-3-ethoxycarbonylindol methylen activ compound deriv titl ring system test panel human tumor cell line show inhibitori activ wide rang cancer cell line micromolar concentr
soft tissu sarcoma frequent carri p53 mutat reduc chemotherapeut respons especi malign fibrou histiocytoma mfh reveal reduc ifosfamid chemosensit compar sarcoma entiti first studi analyz mfh cell effect express pathwai p16-cdk4-rb p14arf-mdm2-p73 regul cell cycl aim identifi candid gene possibl involv anti-apoptot respons p53-defici mfh cell chemotherapi pcr real-time rt-pcr confoc laser scan microscopi appli primari cultur mfh cell contain defect p53 gene cultur treat differ concentr non-treat mfh cultur serv neg control threshold concentr 100 microm determin spare major cell wherea higher quantiti caus complet apoptosi data collect period show mfh cell surviv 100 microm overexpress kinas gene cdk4 oncogen mdm2 factor similar strong increas observ protein level both protein contrast protein analyz detect addition mfh cell induc complex pattern mdm2 mrna splice abnorm mrna transcript carri novel mdm2 missens mutat effect neither observ non-treat cultur nor cultur complet induc spontan apoptosi specul induct gene cdk4 especi mdm2 involv anti-apoptot mechan p53-neg mfh cell toler vitro experi necessari test whether novel candid gene favor develop chemoresist whether mdm2 mrna splice variant contribut process vivo
vitamin riboflavin act strong radiat protect agent escherichia coli bacteria ab1157 aerat media abil reinforc addit vitamin under influenc gamma-radiat vitamin complet suppress cytostat activ mitomycin mmc presenc both vitamin mmc convert effici cytostat rather strong radiat protect agent effect open pathwai specif protect normal mammalian cell high o2-content under treatment ioniz radiat
background alpha-emit nuclid 211at great interest radionuclid therapi coupl tumor-target biomolecul e.g epiderm growth factor egf receptor overexpress malign howev almost inform concern cellular process astatin target agent avail materi method indirectli astatin egf [211at]-benzoat-egf studi cellular process a-431 carcinoma cell comparison data concern [125i]-benzoat-egf result biolog half-life astatin 3.5 longer half-life iodin label 1.5 increas half-life due longer retent internalis astatin radioact maximum accumul astatin label occur later 4-6h iodin label 2-4h indic slower excret astatin confirm experi 211at/1251-benzoat-egf conclus long retent astatin advantag radionuclid therapi
background phase studi weekli low-dose administr cisplatin cddp docetaxel doc combin concurr convention fraction radiotherapi design locoregion advanc head neck cancer patient method twelv patient treat vari level doc level mg/m2/week level 7.5 mg/m2/week level mg/m2/week cddp constant mg/m2/week four cohort three patient radiat given 1.8-2.0 gy/fraction total dose 60-70.2 result hematolog toxic except lymphocytopenia minim mucos toxic especi grade mucos common dose-limit toxic grade pain level reach maximum toler dose grade toxic observ complet respons rate rang variou dose level conclus concurr chemoradiotherapi seem promis treatment modal level recommend dose phase studi
conform radiotherapi intens modul radiotherapi imrt commonli lead larg integr dose patient electron reduc integr dose suitabl treat deep-seat tumour ow limit penetr combin electron photon beam dose distribut improv studi possibl explor us mixtur electron photon beam deep-seat target volum head neck region treatment plan made five simul head neck cancer case mix electron photon beam plan construct us manual iter procedur photon imrt plan optim automat both electron photon beam collim comput control multi-leaf collim mlc both method abl produc clinic accept plan criteria target dose met similarli both criteria critic organ integr dose outsid plan target volum ptv show tendenc lower plan compar photon imrt plan mix electron photon techniqu potenti treat deep-seat tumour reason expect computer optim tool coupl mix electron photon beam techniqu treatment goal readili achiev us sole pure photon imrt
aim retrospect studi analyz outcom radic radiotherapi 292 patient bladder cancer identifi prognost factor local control surviv median ag 72.3 year rang 45-83 year median follow month rang 18-121 month patient treat us standard 3-field techniqu fraction tumor bladder elect lymph node treat dose rang complet respons obtain patient 3-month control howev patient initi develop recurr follow-up 3-year 5-year overal surviv rate respect perform statu t-stage macroscop complet turb hydronephrosi serum creatinin independ prognost factor overal surviv import select patient cur intend radiotherapi radiotherapi acut transient side effect record patient sever bowel complic record patient radiotherapi patient develop intestin reaction requir surgeri three patient cystectom becaus sever radiat reaction bladder 5-year follow-up actuari risk complic requir surgeri treatment-relat mortal
articl describ optim process special design local region hyperthermia order achiev desir specif absorpt rate patient base genet algorithm coupl finit element formul optim method appli real human organ mesh assembl computer tomographi scan finit element formul us calcul electromagnet field patient achiev radiofrequ microwav sourc space discret perform us incomplet first order edg element spars complex symmetr matrix equat solv us conjug gradient solver potenti project pre-condit formul valid comparison calcul specif absorpt rate distribut phantom temperatur measur genet algorithm us optim specif absorpt rate distribut predict phase amplitud sourc lead best focal object function defin specif absorpt rate ratio tumour healthi tissu sever constraint regard specif absorpt rate tumour total power patient prescrib result obtain two type applic waveguid annular phase arrai present show faculti develop optim process
proteasom abund multicatalyt enzym complex present cytoplasm nucleu eukaryot cell primari function proteasom degrad protein onc thought act primarili cellular garbag dispos remov damag misfold protein cell proteasom known remov variou short-live protein regul cell cycl cell growth differenti regul turnov protein via time degrad recycl proteasom plai critic role mainten cellular homeostasi substrat proteasom includ cell-cycl regul signal molecul tumor suppressor transcript factor antiapoptot protein cellular protein recycl through proteasom articl discuss structur function proteasom role malign cell therapeut target
target molecular therapeut tailor genet abnorm caus tumor progress modul certain signal pathwai aberr cancer cell potenti provid effect nontox approach therapi broad rang cancer agent target bcr-abl imatinib mesyl [formerli known sti-571] gleevec novarti pharmaceut corp east hanov retinoid receptor fusion protein all-tran retino acid erbb-2 her2/neu trastuzumab herceptin genentech inc south san francisco epiderm growth factor receptor imc-c225 zd1839 phosphatidylinositol 3-kinas pathwai cci-779 induc remark nontox respons subset patient cancer abnorm correspond signal transduct cascad achiev success individu therapi specif compon aberr signal pathwai drive pathophysiolog tumor identifi patient molecular diagnost identifi patient target aberr link molecular diagnost effect molecular therapeut will necessari translat concept approach will alter outcom patient cancer addit intermediari marker molecular imag techniqu us identifi biolog relev dose suffici inhibit target interest review focus p13k pathwai novel molecul target pathwai illustr question challeng underli implement molecular therapeut breast ovarian cancer
cancer cell express excess level bcl-2 pose major problem deliveri cur therapi most treatment cancer involv chemotherapi induc apoptot process therapi result diseas control period time failur initi apoptosi result acquir resist limit effect treatment common hematopoiet solid malign ultim death malign still occur variou anti-apoptot protein bcl-2 famili local mitochondria appear involv resist mechan howev recent advanc understand malign cell biologi achiev through both genom proteom made possibl explor novel approach direct re-establish sensit chemotherapi present attract strategi cancer treatment articl discuss achiev lower bcl-2 anti-apoptot protein express us antisens oligonucleotid altern function antagon bcl-2 us ligand mitochondri benzodiazepin receptor
novel therapi target multipl myeloma cell cell-patient bone marrow interact bone marrow milieu overcom resist convent therapi preclin model clinic trial both proteasom inhibitor bortezomib immunomodulatori drug revimid celgen corpor warren gone laboratori bench bedsid year achiev respons patient relaps refractori undergo clinic evalu alon combin convent novel therapi treatment patient earlier diseas cours offer great promis improv patient outcom
object year signific improv life expect among peopl intellectu disabl incid ag-associ diseas cancer rise aim studi compar rate cancer peopl found gener popul method inform 9409 individu regist disabl servic commiss western australia link state cancer registri 200 case cancer detect 156 729 person-year standardis incid ratio sir confid interv calcul both sex separ 5-year ag group period 1982-2001 same procedur adopt estim sir specif type cancer result ag-standardis incid cancer peopl significantli differ gener popul howev male observ significantli increas risk leukaemia brain stomach cancer reduc risk prostat cancer leukaemia corpu uteri colorect cancer significantli higher femal conclus health practition need awar improv life expect incid cancer peopl like rise proactiv health promot campaign need peopl like poor user screen servic symptom report advanc treatabl stage diseas
epiderm growth factor egf -mediat ca2+ signal multipl cell line deriv human glioma a431 epidermoid carcinoma cell line observ us fluoresc videomicroscopi bath applic egf evok oscillatori increas [ca2+]i differ human glioma cell line well a431 cell line effect block egf receptor tyrosin kinas inhibitor gefitinib erlotinib well egfr antibodi cetuximab addit acut ca2+ signal respons transient exposur egf potenti subsequ ca2+ signal respons stimuli tumor cell transient expos egf minut show sustain increas propag intercellular ca2+ wave previous shown involv releas atp activ purinerg receptor cell transient expos egf show sustain potenti ca2+ signal respons atp contrast acut ca2+ signal respons egf sustain potenti purinerg intercellular signal block gefitinib erlotinib block cetuximab result indic acut ca2+ signal respons requir tyrosin kinas activ sustain potenti intercellular signal occur via distinct pathwai distinct intra- intercellular ca2+ signal pathwai mechan egf modul growth migrat tumor cell
bin1/amphiphysin2 gene encod sever altern splice bar adapt protein implic membran-associ nuclear process bin1 express attenu tumor progress bin1 splice isoform local nucleu displai tumor suppressor properti properti reflect abil isoform interact suppress cell transform activ c-myc effect bin1 delet oncogen c-myc transform gene gaug directli here report target delet bin1 enhanc neoplast charact primari murin embryo fibroblast mef cotransform c-myc mutant grasg specif bin1 loss accentu spindl morpholog transform cell increas anchorag-independ prolifer promot tumor format syngen host effect specif recapitul cell transform viral oncoprotein mutant ra bin1 splice isoform associ endocytot complex effect bin1 loss correl gener defect receptor-mediat endocytosi howev bin1 loss increas sensit paclitaxel drug affect endocytot traffick disrupt microtubul dynam e1a transform mef bin1 loss reduc suscept apoptosi trigger tumor necrosi factor-alpha effect associ precoci nuclear traffick nf-kappab find offer novel line support hypothes role bin1 limit malign growth possibl neg modifi anti-progress gene
prolong us aspirin and\or non-steroid anti-inflammatori drug induc partial regress sporad adenoma adenoma adenomat polyposi coli apc emerg colon cancer develop sporad adenoma specif inhibitor cyclooxygenas type cox2 induc upper lower digest tract advers event non-specif anti-inflammatori drug better toler allow long-last us patient apc time don't know treatment abl prevent develop cancer rectum duodenum patient paper will discuss scientif proof potenti interest cox2 inhibitor treatment paf
tradit pain manag strategi cancer pain reli us opioid nonsteroid anti-inflammatori drug nsaid adjuv analges howev substanti advers effect associ us left patient depend option effect treatment recent advanc understand pain pathophysiolog mechan led develop novel therapeut cyclooxygenas cox -2-specif inhibitor coxib establish efficaci treatment chronic acut pain compar tradit nsaid degre gastrointestin complic platelet inhibitor effect tradit nsaid numer studi shown coxib efficaci manag chronic acut pain variou clinic set includ postop pain superior safeti profil coxib conjunct compar efficaci nonselect nsaid support us coxib balanc analges regimen provid potenti incorpor coxib pain manag algorithm us treat cancer pain
irradi heart beget differ complic pericardi diseas most common manifest thorac irradi lymphoma hodgkin's diseas lung breast cancer complic advers effect everi structur heart potenti injuri mediastin irradi includ acut late pericard cardiomyopathi valvular diseas conduct abnorm pathophysiolog variou syndrom probabl similar start prior microvascular injuri lead subsequ myocardium ischemia caus late fibrou scar acut pericard asymptomat clear spontan late pericard affect approxim patient irradi dose exce dose mortal rate cardiomyopathi rare asymptomat long time unrecogn coronari arteri diseas diagnos patient beget multifari sequela like myocardi infarct valvular abnorm cardiac rhythm chang coronari arteri diseas like occur patient young time irradi &lt year cardiovascular risk factor associ incid mortal rate valvular defect 0.5 respect conduct dysfunct patient radiat-induc heart complic seem relat total dose irradi tissu volum fraction size cardiac complic appear month year incident irradi heart appropri screen long-term cardiac follow-up patient essenti
5-fluorouracil 5fu larg emploi antimetabolit respons sever well-known toxic like hand-foot syndrom diarrhoea mucos leucopenia cardiotox 5-fu known uncommon usual life-threaten incid vari 1.5 physiopatholog controversi recent data suggest myocardi toxic clinic present includ chest-pain cardiac arrythmia myocardi infarct global cardiac failur electrocardiograph featur usual aspecif ischem sign main treatment stop 5-fu infus introduc symptomat cardiolog treatment prognosi good mortal rang 2.2 case symptomat cardiotox secondari prophylaxi remain controversi
trastuzumab combin chemotherapi demonstr signific improv time progress surviv metastat breast cancer patient overexpress her-2 cardiac toxic unexpect side effect incid cardiac dysfunct depend prior current anthracyclin exposur mechan action involv cardiac toxic unclear discuss articl incid physiopatholog risk factor predict factor patient manag cardiotox trastuzumab
other cancer agent lead cardiovascular toxic apart anthracyclin 5-fluorouracil trastuzumab ioniz radiat paclitaxel high-dose cyclophosphamid ifosfamid mitomycin irinotecan cardiotox unusu certain hormon therapi extens us breast prostat cancer thromboembol cardiovascular event increas estrogen synthet progest tamoxifen becaus major toxic relat intraven interleukin-2 subcutan interleukin-2 regimen develop allow improv cardiovascular toler interferon frequent associ cardiotox befor treatment initi risk factor favour cardiac toxic evalu risk factor relat cancer agent patient tumour uncommon toxic event gener popul frequent high risk patient therapeut option influenc uncommon toxic event high risk patient
year increas cure rate childhood cancer leukemia almost facilit observ middl long-term sequela particularli cardiovascular origin after-effect consequ cytotox damag cell cardiovascular system particular anthracyclin radiotherapi combin us destruct lesion myocyt greatli hinder capac cardiac muscl hypertrophi meet need bodili growth pregnanc certain intens sport activ endotheli cell acceler earli arteriosclerot process potenti caus sudden death case ostial stenosi phenomena build time togeth usual adult cardio-vascular risk factor final cardiac tissu pericardi valvular endocardium autonom nervou tissu escap cytotox effect give rise pericard calcif valvular leak arrythmia conduct abnorm result excess cardiac mortal on major concern paediatr oncologist along secondari tumour leukaemia articl analys physiopatholog consequ asymptomat clinic togeth diagnost screen follow-up method patient encourag lifestyl modif appropri possibl treatment befor appear cardiac failur myocardi infarct sudden death cytotox drug high-dose cyclophosphamid amsacrin 5-fu tubulin act agent mention result cardiac toxic usual dose-cumul
differ anticanc treatment radiat therapi chemotherapi target therapi cardiac toxic toxic clinic cardiac insuffici reduc global benefit treatment differ anticanc drug cardiotox frequent us anthracyclin combin anthracyclin agent like trastuzumab paclitaxel improv treatment result increas risk cardiac toxic differ strategi develop evalu concern prevent cardiac toxic induc anthracyclin us potenti cardiotox anthracyclin direct comparison adjuv trial modif anthracyclin infus us becaus technic problem develop therapeut strategi offer opportun optim combin differ treatment increas cardiac toxic us cardioprotect agent befor anthracyclin infus dexrazoxan possibl howev indic well defin despit exist efficaci result
estim real figur potenti patient recruit hadrontherapi carri survei directli radiat therapi depart east franc on-dai survei result present account case potenti indic among 532 evalu medic record
hadrontherapi centr activ world 000 patient treat almost 4000 ion physic select high rel biolog effici rbe repres rational us ion treatment tumour clinic result promis justifi construct centr present main characterist cnao centro nazional adroterapia oncologica possibl integr nationwid network italian project start 1991 thank activ tera foundat financ italian govern 2002 cnao will built pavia start clinic activ 2007 equip will includ synchrotron treatment room mainli devot carbon ion abl deliv proton centr abl deliv 000 fraction year realiz cnao part ambiti project set integr nation network need hadrontherapi centr defin epidemiolog studi base italian tumour registri show almost 900 patient elect treat protontherapi 000 includ clinic trial consid ion us radioresist tumour affect 000 patient/year estim 10-15 i.e 3000-4000 patient benefit ion therapi realiz nationwid network possibl link larger european network will help make avail hadrontherapi larg part popul
background plan medaustron hadron therapi facil design compar proton carbon ion beam therapi under same technic condit calcul number potenti patient hadron therapi epidemiolog estim cancer incid avail inclus percentag patient routin refer convent radiotherapi materi method nationwid prospect survei collect diseas treatment relat data patient receiv convent radiotherapi treatment facil epidemiolog cancer incid statist austria 1999 correl number patient receiv convent radiotherapi base publish clinic experiment result proton carbon ion therapi calcul patient's subgroup suitabl hadron therapi perform five european univers hospit involv hicat cnao etoil medaustron project us mean valu univers specif percentag per tumour site number potenti patient estim result austria total 3783 patient start radiotherapi studi period month result approxim number 15132 patient per year number potenti patient estim 2044 per year repres 5.6 newli diagnos cancer patient 13.5 irradi cancer patient conclus clear place hadron therapi facil austria base pattern care radiotherapi cancer incid indic
purpos austria nation survei conduct med austron/osterreichisch gesellschaft radio--onkologi radiobiologi und medizinisch radiophysik ogro order estim indic patient number radiotherapi treatment plan procedur perform austrian radiotherapi institut result correl incid rate austrian cancer registri determin pattern radiotherapi practic austria materi method radiotherapi depart austria data patient receiv irradi month 2002/2003 period assess basi questionnair number treat patient indic paramet diseas stage histolog treatment modal evalu result analys regard differ tumour group accord academ non academ hospit correl epidemiolog data cancer incid result total 3783 patient regist period accord differ tumour entiti percentag patient receiv radiotherapi initi treatment vari e.g brain tumour breast cancer prostat cancer most frequent indic radiotherapi per radiotherapi depart breast cancer rang -35 mean urolog tumour rang -27 mean bone metastas mean rang -17 conclus austria breast cancer urolog tumour bone metastas repres most common indic radiotherapi among differ depart variat indic radiotherapi observ studi first evalu radiotherapeut manag austria
present modern photon deliveri techniqu permit high dose isodos conform similar proton case howev proton advantag appear still present target volum higher degre complex concav select histolog site notabl skull base tumor proton establish gold standard photon data yet duplic proton result clinic practic proton radiat therapi offer superior dose distribut reduc low-dose integr irradi volum avoid function cosmet side effect children proton present acknowledg radiat oncolog commun expect gain similar recognit adult patient advantag proton disadvantag photon constitut inher physic gap will like long last prioriti proton irradi advantag shift decad clinic advantag remain suffici signific import justifi develop instal proton radiat facil worldwid
april 2001 hyogo ion beam medic center hibmc open first facil world provid ion beam therapi us type beam proton carbon-ion will introduc hibmc report result clinic studi gener practic
background purpos carbon ion beam provid physic biolog advantag photon studi summar experi carbon ion radiotherapi heavi ion medic acceler chiba himac nation institut radiolog scienc materi method june 1994 august 2003 total 1601 patient variou type malign tumor enrol phase i/ii dose-escal studi clinic phase studi malign glioma patient receiv carbon ion radiotherapi alon fraction number overal treatment time fix tumor site given on field per dai dai per week dose-escal studi total dose escal increment ensur safe patient treatment determin appropri dose level result initi dose-escal studi sever late complic recto-sigmoid colon esophagu observ patient receiv high dose level prostat uterin cervix esophag cancer advers effect howev shortli disappear result determin safe dose level becaus improv irradi method carbon ion radiotherapi shown improv outcom tumor entiti local advanc head neck tumor particular non-squamou cell histolog includ adenocarcinoma adenoid cystic carcinoma malign melanoma earli stage nsclc local advanc nsclc local advanc bone soft tissu sarcoma suit surgic resect local advanc hepatocellular carcinoma local advanc prostat carcinoma particular high-risk patient chordoma chondrosarcoma skull base cervic spine post-oper pelvic recurr rectal cancer treatment malign glioma pancreat uterin cervix esophag cancer investig dose-escal studi rational us short-cours regimen due superior dose local uniqu biolog properti high-let beam proven treatment nsclc hepatoma fraction number successfulli reduc 4-12 fraction deliv 1-3 week type tumor includ prostat cancer bone/soft tissu sarcoma head/neck tumor equal possibl appli therapi much shorter treatment time compar convent regimen conclus carbon ion radiotherapi due physic biolog advantag photon provid improv outcom term minim toxic high local control rate local advanc tumor patholog non-squamou cell type tumor us carbon ion radiotherapi hypofraction radiotherapi applic larger dose per fraction reduct overal treatment time compar convent radiotherapi enabl
proton characteris low let compar photon electron improv physic depth dose distribut indic proton i.e ocular melanoma chordoma chondrosarcoma base skull cervic spine accept radiat oncolog commun treatment choic other still under evalu e.g meningioma local advanc nasopharynx tumour paediatr tumour neutron biolog advantag high let distribut dose most case suboptim despit radiobiolog argument lead expect neutron benefit patient tumour resist photon slowli grow contain high proport hypox cell clinic evid rational potenti high let advantag local extens think current jargon word extend english. salivari gland tumour local extens extend prostat carcinoma slowli grow inoper soft tissu sarcoma adenocarcinoma adenoid cystic carcinoma paranas sinus melanoma rectal carcinoma light ion combin high let advantag neutron improv physic depth dose distribut proton opportun offer optimis distribut dose open era high-let particl especi deepli situat x-rai resist tumour us neutron beam restrict low qualiti depth-dose profil preliminari result encourag
carbon ion radiat therapi avail german ion research center gsi darmstadt germani decemb 1997 patient treatment pilot project carri radiat oncologist univers heidelberg cooper depart biophys gsi divis medic physic german cancer research center heidelberg research center rossendorf patient treat three beam time block dai per year basic physic research center gsi overal capac per year patient main purpos pilot project investig carbon ion radiat therapi differ tumor entiti clinic phase i/ii trial manuscript updat result clinic phase i/ii trial carbon ion chordoma low grade chondrosarcoma skull base summar current statu ongo phase i/ii trial extracrani chordoma low grade chondrosarcoma
exchang clinic inform essenti develop progress radiat oncolog goal achiev through gener harmon method report icru involv sever decad continu effort harmon report dose standard method us determin dose point volum dose deliv requir report proton ion beam therapi principl similar possibl report current radiat therapi modal howev proton ion therapi own clinic technic uniqu particular requir definit clinic radiobiolog technic concept strict qualiti assur programm effici safe clinic applic current icru definit volum review gross tumour volum gtv clinic target volum ctv plan target volum ptv organ risk oar plan organ risk volum prv treat volum refer volum irradi condit absorb dose report togeth point volum dose deliv addit weight factor rbe introduc take account rbe relat weight dose rbe report
especi ion therapi effici form patient throughput becom increasingli import here patient posit treatment room isocent kei aspect order ascertain high qualiti nonetheless suggest altern rigidli instal couch paradigm form real-time patient posit onhand ceil mount infrar photogrammetr system give posit inform novel treatment couch degre freedom integr roll platform medaustron treatment plan room plan forseen rigidli instal treatment couch
background purpos clinic target volum thorax abdomen typic expand account inter- intrafract organ motion usual expans base clinic experi planar observ target motion simul precis 4-dimension motion margin specif patient improv dose coverag mobil target yet limit unnecessarili larg field expans studi approach target move tumor entir treatment process treatment plan beam deliveri materi method radio-opaqu marker implant under guidanc liver gross tumor peripheri organ motion light respir volumetr imag comput tomographi marker motion acquir fluoroscopi compar 4dct data treatment daili diagnost x-rai imag captur end-exhal -inhal patient setup target local result base time-resolv data target volum design account respiratori motion treatment motion tumor deriv 4dct consist fluoroscop motion analysi radiograph acquir treatment room enabl millimet-level patient set-up assess target posit rel boni anatomi daili posit variat boni anatomi implant marker observ conclus imag guid therapi base 4dct imag fluoroscop imag studi daili gate diagonst energi set-up radiograph develop improv beam deliveri precis monitor intern target motion entir treatment process will ensur adequ dose coverag target spare maximum healthi tissu
paper describ gener methodolog realist reconstruct anim anatom organ fact scope conform radiotherapi hadron therapi applic want simul motion shape alter intern anatom object input knowledg treatment plan reconstruct particl system us firstli surfac shape consid organ comput set scan section volum defin surfac fill particl coher object maintain due us classic lennard-jone inter particl forc work permit studi impact organ movement treatment prostat lung cancer particl system suitabl integr radiat dose evalu softwar develop european biom2 project current support french etoil project
intens modul activ beam deliveri like magnet raster scan strongli reli target immobilis target motion avoid interfer scan procedur tumour displac destroi volum conform prototyp setup onlin motion compens 3d-omc scan particl beam describ transfer full potenti volum conform irradi move target
1997 radiotherapi unit us fast carbon ion oper gsi intens-control magnet raster scanner togeth synchrotron allow fast energi variat enabl uniqu method pure activ dose shape three dimens contribut describ necessari step establish treatment plan system novel modal discuss requir physic beam model radiobiolog model base chose implement home-grown pencil beam model describ ion-tissu interact local effect model calcul rbe voxel-by-voxel given larg number degre freedom biolog dose optim achiev mean invers treatment plan ion-relat aspect collect trip98 softwar biolog dosimetri measur cell surviv two dimens turn good wai verifi model predict well actual irradi procedur show patient exampl outlin futur step dedic clinic facil light ion
gsi carbon ion radiotherapi facil establish first complet activ beam shape system heavi ion us energi variat synchrotron pencil beam scan introduct activ beam shape system carbon ion consider impact design treatment plan system tp tp account capabl beam deliveri biolog model need calcul rbe result vari depth dose modul tp us clinic routin carbon ion describ us treatment plan studi outlin clinic trial carbon ion therapi primari therapi chordoma chondrosarcoma base skull complet 2001 current carbon ion therapi boost treatment togeth convent conform photon therapi imrt under investig clinic trial adenoid cystic carcinoma chordoma chondrosarcoma cervic spine sacrococcyg chordoma treatment plan studi compar carbon ion therapi imrt us optim combin therapi optim beam-line design alreadi complet analysi uncertainti treatment plan start investig rang uncertainti stem imag uncertainti come beam deliveri plai minor role attempt ass uncertainti introduc treatment plan biolog model done us phantom verif calcul cell surviv level clinic trial plan studi special import upcom clinic ion facil heidelberg univers hospit
us 12c beam 200 amev kinet energi product secondari fragment nuclear reaction thick water absorb 12.78 investig fast neutron energet charg particl a-particl emit forward hemispher identifi baf2/plastic-scintil detector telescop neutron energi spectra record variou angl us time-of-flight techniqu neutron emiss forward peak energi spectrum show broad maximum half energi per nucleon primari 12c ion total yield fast neutron emit forward hemispher integr energi rang 500 mev found 0.43 +/- 0.1 per primari ion dose contribut fast neutron patient treatment carbon ion estim total treatment dose
positron emiss tomographi pet imag radioact distribut induc therapeut irradi present feasibl method situ non-invas monitor radiooncolog treatment ion beam clinic implement imag technolog experiment carbon ion therapi facil gesellschaft fr schwerionenforschung gsi darmstadt germani outlin interact approach pet guid quantif local dose deviat respect treatment plan present
present bang polym-gel dosimetri us magnet reson imag mri appli dens ioniz radiat carbon ion beam bang polym-gel irradi monoenerget 12c ion energi 205 mevu irradi gel dose 100 perform radiotherapi facil gsi darmstadt germani comparison spars ioniz radiat data obtain photon radiat object examin satur effect dens ioniz radiat occur high valu linear energi transfer let dose respons unknown mix radiat field primari carbon ion facilit convers measur signal dose model calcul propos model reli heavi ion track structur experiment determin photon respons
atom forc microscopi phix174 plasmid irradi vitro us visualis dna fragment induc heavi ion compar fragment pattern obtain x-irradi fragment distribut induc low ion fuenc found much shift small fragment size distribut obtain correspond dose x-rai averag fragment length found significantli smaller full plasmid length singl ion travers
background purpos reaction human tumor cell mammalian normal tissu irradi low energi proton x-rai examin materi method irradi facil vertic proton beam set tandem acceler univers erlangen u-138mg human glioblastoma cell b14 hamster fibroblast irradi 5.7 7.0 mev proton let 7.27 6.23 kev/microm 120 x-rai inactiv measur coloni form assai induct repair dna doubl strand break dsb constant field gel electrophoresi cell cycl control imag cytometri result obviou reduct shoulder dose effect curv determin effect pronounc glioblastoma cell line rbe surviv measur 1.78 +/- 0.09 glioblastoma cell 1.18 +/- 0.06 b14 fibroblast induct dna dsb glioblastoma cell show rbe 0.96 +/- 0.06 24h repair time rbe 2.63 +/- 0.07 calcul proton larger endur effect arrest cell cycl x-rai hour irradi rbe 1.57 +/- 0.05 calcul conclus effect higher let irradi distinct tumor cell normal tissu both cell line show higher rbe cell surviv valu 1.1 normal us proton therapi repair capac dna dsb reduc low energi proton irradi arrest induc larger degre experi need elucid reason lower cell surviv
purpos few studi high let radiat-induc cell cycl arrest avail open question still remain concern magnitud persist control cell cycl inhibit high-let exposur intent review focu cell cycl distribut irradi popul cell system us normal mutant tumor cell relev publish data summar conclus compar isodos high-let irradi potent induc cell cycl delai low-let irradi gener pronounc delai g2-phase observ increas let role tp53 relat effect still controversi dose- let- depend increas cell arrest g1-phase well observ studi present indic larg fraction normal fibroblast irradi g1-phase reseed exposur re-enter cell cycl remain perman arrest express cell cycl regulatori protein case appear pronounc high let fundament differ observ low- high-let irradi
background purpos previous found drink beer reduc chromosom aberr blood lymphocyt collect irradi vitro studi investig radioprotect activ beer-administr bone marrow intestin mice method c3h/he femal mice receiv oral administr beer ethanol salin dose ml/mous min befor whole bodi irradi 137cs gamma rai let kev/microm carbon ion radioprotect activ estim us 50/30 dose requir kill mice dai microcoloni techniqu intestin result 50/30 beer-administ mice significantli increas comparison salin administ mice 50/30 gamma-rai 7.8 &lt 0.05 7.6 7.3 beer- ethanol- salin-administ group respect 50/30 carbon ion 6.6 &lt 0.05 6.2 5.9 beer- ethanol- salin-administ group respect crypt surviv semi-logarithm plot dose well fit linear regress line dose reduct factor drf d10 beer- ethanol-administ mice gamma rai 1.09 1.08 respect drf d10 beer- ethanol-administ mice carbon ion 1.08 1.07 respect conclus radioprotect beer-administr due radic-scaveng action ethanol contain beer
radiobiolog studi proton beam start first half centuri scientif commun profit lawrenc idea acceler proton becam soon clear radiat favour us clinic applic biolog effect proton deepli investig wide energi rang sever biolog end-point studi nowadai partial overlap research field expand aim radioprotect astronaut major concern becaus long-term man space mission foreseen
success cancer patient surviv local tumor control hadron radiotherapi warrant discuss potenti secondari late effect radiat studi late-appear clinic effect particl beam proton carbon heavier ion rel field few data howev clinic inform avail pioneer hadron radiotherapi program usa japan germani switzerland paper will review avail data late tissu effect particl radiat exposur discuss import futur hadron therapi potenti late radiat effect associ irradi normal tissu volum risk case reduc hadron therapi howev normal tissu present hadron treatment volum demonstr enhanc respons compar convent mode therapi late endpoint concern includ induct secondari cancer cataract fibrosi neurodegener vascular damag immunolog endocrin hereditari effect low-dose tissu effect tumor margin need studi need acut molecular studi underli late effect hadron therapi
sensit healthi tissu limit radiat therapi most technolog progress radiotherapi along histori devot improv spare healthi tissu increas tumor dose us hadron justifi first neutron radiobiolog consider high rbe oxygen effect proton ballist consider bragg peak neutron ballist unfavour side effect import larg deep tumor irradi indic dramat reduc recent studi late effect high rbe irradi carri renew us hopefulli larg scale high rbe beam carbon ion demand apprais radiat toler healthi tissu photon neutron experi drawn typolog late effect time schedul observ iii equival dose associ observ late effect dose limit accord type tissu accept advers effect secur requir rbe part beam irradi healthi tissu commun scale descript late effect will decid biolog mechan late effect associ slow cellular lost micro vascular failur activ fibrosi will need investig frame high rbe irradi
background purpos rel biolog effect rbe fast-neutron beam proton beam carbonion beam determin us biolog criterion intestin crypt regener mice i.e vivo system beam us plan clinic cancer therapi applic addit rbe epitherm neutron beam us plan boron neutron captur therapi bnct determin boron administ goal program improv exchang inform center facilit interpret result increas safeti clinic applic materi method visit center same techniqu appli same condit same radiobiolog team number regener crypt per circumfer score 3.5 dai singl fraction total bodi irradi control irradi perform local us cobalt-60 unit mice random accord radiat qualiti dose level result fast neutron beam rbe ref cobalt-60 gamma rai increas decreas energi approxim 1.7 +be neutron approxim 2.4 14.5 +be neutron addit specif facil depend nuclear reaction target collim type proton beam rbe ref cobalt-60 gamma rai refer posit middl 7-cm spread bragg peak sobp rang 1.08 1.18 differ approxim 6-8 accord mode beam product deliveri rbe sobp 5-10 higher middl sobp carbon ion beam studi nir chiba japan rbe significantli increas depth rel gamma rai rang 1.3 initi plateau 1.6 1.7 middl 1.9 6-cm sobp bnct beam radiat qualiti particular rel contribut differ dose compon vari rapidli depth depend strongli arrang irradi set-up e.g presenc back scatter materi moreov total dose rate highli variabl 0.05 approxim 0.5 gy/min accord power reactor wide rang rbe valu ref gamma rai obtain rbe 1.4 2.2 shallow depth 1.5 2.5 discuss conclus intestin crypt regener mice vivo system perfectli suitabl perform intercomparison center appli differ type non-convent radiat qualiti proven reproduc reliabl accur becom progress recogn worldwid part qualiti control procedur beam stress observ rbe intestin crypt cell singl high dose provid radiobiolog character radiat qualiti us rbe weight factor clinic prescript
data report literatur neoplast transform induc cultur cell light charg particl compar analyz function let dose protract light charg particl rbe transform maximum 120 kev/microm major data suggest rbe valu surviv transform similar magnitud dose protract effect transform induct depend dose dose rate radiat qualiti
research field biolog effect heavi charg particl need both heavi-ion therapi hadrontherapi protect exposur galact cosmic radiat long-term man space mission exposur condit e.g high- low-dose rate relev endpoint e.g cell kill neoplast transform differ two field clear substanti overlap exist sever research topic three topic discuss short review individu radiosensit mix radiat field late stochast effect heavi ion addit research involv experiment studi space radiat protect heavi-ion therapi will basic us same acceler facil seem import novel acceler facil plan under construct heavi-ion therapi reserv substanti amount beamtim basic studi heavi-ion radiobiolog applic space radiat research
main reason applic heavi ion like carbon radiotherapi enhanc rel biolog effect rbe contrast neutron rbe wide independ penetr depth high energi carbon beam low rbe entranc high rbe target-volum side effect normal tissu small tumor respons maxim paper experiment rbe valu inactiv compil demonstr rbe depend repair capac theoret approach local effect model lem depend us calcul clinic rbe exampl clinic rbe given appli patient treatment
background purpos theoret model mont carlo simul develop aim investig role plai organis interphas dna environment scaveng capac condit induct radiobiolog damag method induct singl- doubl-strand break gamma rai imping differ dna structur e.g linear dna sv40 minichromosom cellular dna simul function environ scaveng capac furthermor yield chromosom aberr induc gamma rai light ion simul purpos develop code explicitli take account dna higher-order organis chromosom territori result conclus simul perform partrac code allow quantif depend dsb ssb both target structur scaveng capac result rel show import dna damag complex nanometr scale interphas chromosom domain micrometr scale process aberr format good agreement found model predict ssb dsb avail experiment data
set four paramet sigma0 kappa cellular track structur model katz fit recent publish data concern human melanoma mammalian v79 cell expos varieti lighter ion mix ion-co60 ion-ion irradi us paramet model predict v79 surviv verifi experiment data rbe-let depend calcul compar experiment data obtain v79 cell exposur 3he 12c 20ne ion beam present track-segment approach us track structur calcul satisfactori heavier ion limit valu predict rbe-let depend proton helium radiotherapi beam region close distal rang particl discuss predict capabl model propos standard report cellular radiobiolog data applic model heavi ion beam radiotherapi
absorb dose fundament quantiti us quantifi exposur biolog system ioniz radiat howev relationship dose biolog effect uniqu vari fraction time factor radiat qualiti irradi condit radiat therapi weight factor us correl absorb dose clinic effect alter irradi condit combin compar differ technic modal well establish therapi modal e.g fraction photon beam therapi gener agreement weight factor reach base linear-quadrat model neutron proton ion therapi differ radiat qualiti current account us divers method almost hospit specif paper review current approach us evalu select weight factor applic clinic practic weight factor take account rbe factor fraction need harmon approach will facilit exchang inform radiat oncolog commun centr us differ technic modal case report treatment absorb dose irradi condit specifi addit weight factor weight dose
framework european network research light ion hadron therapi enlight health econom group develop methodolog assess import invest oper cost innov treatment expect benefit main task estim cost per treat patient cost analysi restrict therapeut phase hospit point view origin methodolog cost assess per treatment protocol develop base standard cost cost relat direct medic activ base product process analysi wherea indirect non direct medic cost alloc protocol us relev cost-driver result cost model will take account specif therapeut protocol well particular european project
ion beam therapi facil present under construct depart clinic radiolog univers heidelberg germani will first dedic hospit-base irradi facil proton heavier ion europ capac 1000 patient treatment per year plan facil compris two horizont-fix beamlin patient treatment plu fix-beam experiment area addit world-wide first scan ion gantri under construct facil fulli reli activ beam deliveri method intens-control rasterscan techniqu avail differ ion speci rang proton oxygen under ident condit optim support clinic trial aim clarifi question particl speci best suit individu indic linac-synchrotron combin will deliv librari energi- focu- intens-variabl pencil-beam ion speci dose-deliv scan system treatment station avail energi correspond water-equival rang intens-control rasterscan techniqu allow administr invers plan biolog optim dose distribut have utmost precis facil will equip state-of-the-art imag modal well in-situ positron-emiss-tomographi pet commiss differ section schedul 2006 pre-clinic oper will start earli 2007 follow routin patient treatment
1991 author involv italian institut nuclear physic infn r&amp work field hadrontherapi 1992 tera foundat creat purpos form emploi peopl fulli devot design promot construct hadrontherapi centr itali europ present contribut describ main project tera cnao centro nazional adroterapia oncologica statu construct pavia italian centr base optimis medic synchrotron design framework proton ion medic machin studi pimm carri cern 1996 2000 cern med-austro project oncolog 2000 pragu tera partner year tera introduc modif improv origin pimm design produc dub pimm/tera design 2001 construct cnao endors italian govern cnao foundat form five major hospit seat milan pave tera 2003 infn institut particip site chosen 2003 000 close vicin on five hospit san matteo univers hospit pave construct plan forese treatment first patient 2007
paper describ statu design studi austrian ion therapi cancer-research centr project medaustron work perform two year medaustron studi group team spread sever research institut univers clinic full-time member medic univers vienna innsbruck medic univers fotec wiener neustadt collabor medic univers graz hospit wiener neustadt vienna univers technolog research institut cern psi slovak univers technolog bratislava jozef stefan institut ljubljana studi group work cooper gsi darmstadt cnao foundat milan agre aim studi investig conceptu design acceler facil provid optimum treatment condit high-precis activ beam scan cancer tumour both proton carbon ion
recent develop radiat therapi made possibl optim high dose region cover almost target volum shape same time dose level adjac organ risk accept implement imrt intens modul radiat therapi invers treatment plan us alreadi avail technolog forese improv design therapi acceler deliv electron- photon beam will bring advanc benefit broad popul cancer patient proton will gener need most situat improv will insignific moder due larg later penumbra deep proton therapi step us he-ion half penumbra width proton still fairli low-let spread-out bragg peak howev still group patient help advanc tumor radioresist present util low ioniz densiti beam qualiti ultim step therapi develop process optim beam qualiti tumor-normal tissu situat facilit beam qualiti optim light ion need argu radioresist tumor dose-mean let 25-50 ev/nm target optimum tumor cell will lost highest proport through apoptot cell kill superfici tissu will still irradi fairli low let light ion us ideal choic paper light ion facil outlin karolinska univers hospit facilit both dose distribut beam qualiti optim
propos build nation centr light-ion hadrontherapi franc locat lyon rhne-alp region under auspic univers claud bemard lyon-i support research contract rhne-alp region minist research design elabor paper review medic technic characterist project call etoil espac traitement oncologiqu par ion lger dan cadr europen research program associ etoil concern mainli track move organ design in-beam pet detector simul interact carbon ion tissu radiobiolog studi radiosensit toler normal tissu radioresist tumour capit cost need realiz etoil euro expect definit decis build etoil 2004 case centr will treat first patient 2009 routin flux 1000 patient per year will reach year oper cost euro
advanc kidnei cancer account 000 death unit state year immunotherapi typic interleukin-2 interferon-alpha mainstai treatment respons rate low immun-base treatment most patient advanc kidnei cancer succumb diseas sever novel agent current clinic trial show promis refractori diseas compound includ antiangiogen agent raf kinas pathwai inhibitor novel antimicrotubul agent review discuss agent current explor treatment advanc kidnei cancer
signific advanc decad understand cellular biochem molecular effect ioniz radiat combin certain type cytotox drug prodrug well target biolog agent human tumor normal cell same time inform evolv regard specif genet epigenet chang found certain human cancer result alter ioniz radiat damag recognit damag repair process result novel target approach human tumor radiosensit activ area translat clinic research radiat oncolog articl review current statu exist radiosensit regimen
neorx str 0303 random multicent studi compar safeti efficaci 166 ho-dotmp plu melphalan melphalan alon condit autolog peripher blood stem cell transplant subject primari refractori multipl myeloma
goal therapeut intervent posit impact meaning patient outcom efficaci treatment base surrog endpoint thrombolyt therapi venou thromboembol diseas exampl treatment success primarili base radiograph echocardiograph endpoint endpoint symptom relief function capac qualiti life thrombosi recurr surviv thrombolysi lower-extrem deep venou thrombosi doe reduc incid pulmonari embol unclear impact rate post-thrombot syndrom associ increas rate major hemorrhag compar convent anticoagul reserv thrombolysi limb-threaten thrombosi especi young seem prudent current avail evid doe support routin us thrombolyt therapi patient hemodynam stabl pulmonari embol regardless right ventricular function statu risk benefit altern therapi consid therapi guid individu case circumst best avail scientif evid
purpos aim studi evalu experi nci cairo univers manag non- metastet hepatoblastoma improv surviv children reduc oper morbid mortal us preoper chemotherapi patient method biopsi assess extent diseas patient treat 6-hour continu intraven infus cisplatin pla 90mg/m2 dai on follow doxorubicin 20mg/m2 per dai administ hour infus dai four cours preoper chemotherapi patient reassess whenev possibl primari tumor resect treatment complet two cours chemotherapi result twenti children regist januari 1999 decemb 2000 median ag diagnosi month rang dai year patient receiv preoper chemotherapi plado fifteen patient show partial respons tumor shrinkag serial decreas serum alpha-fetoprotein level sixteen patient underw surgeri fourteen complet resect primari tumor 87.5 median durat followup month rang 1-55 month three year diseas-free surviv 68.4 event-free surviv conclus advoc us plado chemotherapi delai surgeri standard treatment children treatment program measur standard
background rocuronium atracurium muscl relax us short-and intermedi-durat surgic procedur studi compar rocuronium atracurium regard neuromuscular efficaci hemodynam chang effect plasma histamin concentr materi method sixti adult patient schedul gener surgic oper last 120 minut clinic random receiv 0.6mg/kg rocuronium group-1 0.5mg/kg atracurium group-2 twitch respons cours four electr stimul baselin heart rate mean blood pressur monitor well histamin level through venou blood sampl result onset time neuromuscular block 54+/-22 second rocuronium group 94+/-26 second atracurium group 0.001 clinic durat intub dose 34+/-6.9 minut rocuronium group 45+/-7.1 minut atracurium group p&lt 0.001 trachea intub second time inject muscl relax patient atracurium group patient rocuronium group 0.005 atracurium rocuronium produc signific reduct mean arteri blood pressur increas heart rate time atracurium result signific increas plasma histamin concentr on three minut 232 149 percentag chang control valu p&lt 0.01 correspond significantli decreas mean arteri blood pressur increas heart rate p&lt 0.01 rocuronium result signific chang plasma histamin concentr 62+/-10 patient atracurium group none rocuronium group clinic sign histamin releas conclus rocuronium provid suitabl condit rapid tracheal intub atracurium associ shorter clinic durat effect mean arteri blood pressur heart rate histamin releas potenc compar atracurium
background propofol us sedat intens care unit aim studi compar efficaci endocrin respons propofol alpha2-agonist dexmedetomidin sedat surgic intens care patient need postop short-term ventil method work random clinic studi conduct sixti adult patient requir postop short term ventil sedat patient alloc randomli receiv infus dexmedetomidin 0.2-0.5 microg/kg/h propofol 0.5-1 mg/kg/h hemodynam paramet ramsai sedat score extub time serum cortisol interleukin-6 il-6 level measur result ramsai sedat score 4.1+/-1 4+/-0.9 propofol dexmedetomidin respect 0.59 total fentanyl dose propofol group 75+/-15 microg compar 15+/-10.5 microg dexmedetomidin group 0.0045 patient receiv dexmedetomidin infus significantli lower heart rate compar patient receiv propofol infus 0.041 pre-infus serum concentr il-6 compar both group post-infus level insignificantli decreas both group compar pre-infus level 0.36 .there intergroup differ serum cortisol concentr 0.231 conclus dexmedetomidin propofol safe sed drug postop mechanich ventil patient patient easili arous co-oper show sign irrit fentanyl analgesia dexmedetomidin group dexmedetomidin propofol inhibit adren function influenc inflammatori respons
electron eject target atom on basic process ioniz radiat interact matter primari electron subsequ secondari interact lead deposit energi around ion trajectori detail knowledg structur ion track kei issu understand radiat effect condens matter import exampl calcul rbe heavi particl doubli differenti electron eject cross section kei input paramet usual data obtain singl collis i.e ga target us condens matter effect consider alter emiss pattern will focu primari ioniz binari encount soft electron emiss common singl atom ga target condens matter special emphasi will given discuss effect condens matter electron transport multipl scatter effect jet-like structur wake effect due collect excit plasmon gaseou target singl collis
prematur chromosom condens pcc techniqu us compar chromatin breakag repair non-cycl cho-k1 cell high let ion low let x-rai irradi both radiat qualiti averag initi number excess pcc fragment increas linearli dose howev frequenc chromatin break follow pattern energi deposit higher let valu reveal cluster due larg number ioniz event concentr small volum cell nucleu consequ distribut pcc chromosom plu excess fragment among cell follow poisson statist x-rai irradi overdispers frequenc observ c-irradi indic singl particl travers through cell nucleu produc multipl chromatin lesion
purpos aim studi evalu treatment result combin therapi surgeri postop craniospin radiotherapi chemotherapi compar treatment postop radiotherapi assess effect extent surgic resect prognosi patient method 1993 2003 children year ag nondissemin medulloblastoma treat postop craniospin radiat therapi fraction craniospin axi supplement posterior fossa dose 1980 cgy fraction total dose daili fraction 1.8 us children receiv chemotherapi form vincristin dose 1.5 mg/m2 given weekli radiotherapi on month complet radiat therapi chemotherapi continu everi week cycl cyclophosphamid 750 mg/m2 vincristin 2mg/m2 maximum dose 2mg altern vincristin carboplatin 500 mg/m2 total altern cycl administ result follow-up period rang 14-132 month median overal surviv oa whole group 49.5 month mean 61+/-38 median progress free surviv pf 47.5 month mean 59.6+/-39 both pf oa better among total resect subtot resect estim 5-y pf both group respect estim 5-y oa subtot resect underw total resect howev differ statist signific 0.1 median pf chemotherapi group 60.5 month mean 72.6+/-41.7 non-chemotherapi group 39.5 month mean 48+/-33.6 differ borderlin signific p-valu 0.06 estim 5-year progress free surviv chemotherapi group chemotherapi group p-valu 025 estim 5-year overal surviv chemotherapi group comparison non-chemotherapi group give borderlin statist signific differ p-valu conclus maximum possibl surgic resect postop radiotherapi adjuv chemotherapi import factor improv outcom manag medulloblastoma
purpos assess variat radiosensit relationship clinic complic potenti applic predict test saudi radiotherapi patient materi method forti-on patient includ studi radiat treatment head neck breast gynecolog cancer skin fibroblast establish radiosensit measur surviv fraction sf2 calcul compar maximum grade acut erythema desquam mucos ulcer late reaction atrophi fibrosi xerostomia telangiectasia follow-up rang 178 month median result sf2 rang 0.16 0.56 mean 0.34 inter-patient coeffici variat intra-patient statist signific correl fibroblast sf2 maximum grade late 0.012 patient acut complic 0.70 patient correl acut late reaction 0.05 patient conclus data reveal wide variat cellular radiosensit correl late reaction radiat treatment radiotherapi patient particularli risk sustain sever complic well benefit individu dose prescript howev predict test altern sf2 requir
background object prospect singl-arm studi carri evalu safeti efficaci neo-adjuv chemotherapi advanc head neck cancer hnc oman materi method studi carri oncolog ear nose throat ent depart muscat oman octob 1998 decemb 2001 elig previous untreat patient confirm diagnosi local advanc non-metastat carcinoma head neck examin maximum three cycl neo-adjuv chemotherapi cisplatin 100mg/m2 dai plu 5-fluorouracil 1gm/m2 continu infus four dai administ follow radic radiotherapi accord primari site main end-point toxic respons rate diseas-free surviv overal surviv result seventi-three patient male femal elig evalu respons toxic median ag studi patient year rang 17-83 year forti-four patient stage iii diseas stage diseas neo-adjuv chemotherapi overal respons [complet respons partial respons observ patient patient clinic patient sixteen patient show stabl diseas patient progress chemotherapi complet radiotherapi rate forti patient clinic confirm patient patient progress diseas median follow-up period month rang 3-48 month initi respons chemotherapi signific effect surviv 0.011 nasopharyng primari significantli associ high longer surviv 0.01 0.02 respect conclus head neck carcinoma common malign oman treatment result cisplatin 5-fu compar favor similar intern studi treatment-relat toxic toler
background purpos thymidin phosphorylas/ platelet deriv-endotheli cell growth factor tp/pd-ecgf angiogen chemotherapeut effect aim work evalu tp/pd-ecgf express gastric adenocarcinoma find correl establish clinicopatholog paramet patient' surviv materi method sampl studi consist fifti-two gastric specimen case chronic gastriti case malign adenocarcinoma immunohistochem stain tp/pd-ecgf done tumor consid posit cell show posit stain result tp/pd-ecgf express significantli higher malign group compar control group 0.001 tumor stromal cell tp/pd-ecgf express malign group significantli correl size tumor mitot count stage group depth invas number lymph node involv perineur invas lymphoplasmacyt tumor associ macrophag tam infiltr vessel densiti furthermor stromal express tp/pd-ecgf significantli correl postop chemotherapi apoptot count surviv analysi reveal proxim tumor small size earli stage neg metastasi absenc perineur invas low neg tumor stromal tp/pd-ecgf express correl better patient' surviv conclus tp/pd-ecgf angiogen function role tumor growth invas metastasi tp/pd-ecgf enhanc effect postop chemotherapi
